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Transplantation of liver has been successful therapy for many liver diseases; 
unfortunately, recipients far out number the available donors. The potential alternative 
approach to solve this profound organ shortage would be to develop a ‘bridging’ device, 
the bioartificial liver-assisted device that would support or replace normal liver function. 
In this research area, the suitable cell carrier, such as micro-carrier, scaffold and 
microcapsules are one of the most important components. Our work involves the 
development of novel galactosylated collagen for a synthetic ECM in 3-D hepatocyte 
culture, which was applied in two 3-D culture systems, microcapsules and porous In situ 
formation hydrogel. 
 
Firstly, Collagen was modified by methanol previously. The microcapsules formed by 
methylated collagen have been proved to enhance cell functions of hepatocytes. In this 
thesis, collagen has been modified by galactose group. The galactose group and peptide 
residues on collagen can not only support hepatocytes, but also enhance cell functions of 
hepatocytes in microcapsules. The novel collagen microcapsules have been characterized, 
including the character of mass transfer and the shape of microcapsules. The cell 
morphology of hepatocytes in galactosylated collagen has been imaged. The relationship 
between materials and cell functions of hepatocytes has been optimized. The effects of 
cell densities, which were seeded in microcapsules, on cell functions of hepatocytes have 
also been optimized. From the results, cell functions of hepatocytes in galactosylated 
 viii
collagen were enhanced much more than those in methylated collagen. Finally, we also 
investigated the influences of galactose group and mechanical support for cell functions 
of hepatocytes. That implies both chemical group and mechanical support are important 
for 3-D hepatocyte culture.   
 
Secondly, In situ gelation galactosylated collagen has also been developed for the 
entrapping hepatocytes in porous PHEMA hydrogel. The in situ forming galactosylated 
collagen can entrap hepatocytes in short time and form the network properly. Otherwise, 
the galactosylated collagen also acts as ECM for enhancing cell functions of hepatocytes 
in porous hydrogel system. The characters of porous PHEMA have been evaluated. The 
formation of in situ galactosylated collagen has also been investigated. Finally, cell 
functions of hepatocytes, which were entrapped by in situ forming galactosylated 
collagen in porous PHEMA scaffold, have been evaluated. From the results, cell 
functions of hepatocytes in this 3-D culture system are much higher than those trapped by 







Chapter1 Introduction and literature reviews 
 
Tissue engineering has the potential to address the transplantation crisis caused by the 
shortage of donor tissue and organs. Through the imitation of nature, tissue 
engineering will be able to address patient’s need; however, a number of challenges 
need to be faced. In the area of cell technology and biomaterials, these including 
suitable ECMs for 3-D cell culture, and suitable formation of cell containers.  
 
Freshly isolated cells rapidly lose hepatocyte morphology and differentiated functions 
when there are cultured in monolayer and suspension. Therefore, this thesis aims to 
develop a new modified ECM protein for liver tissue engineering. In addition, the use 
of conditions allows cells to achieve three-dimensionality; optimizing mass transfer. 
 
Collagen families are one of important matrix materials in vivo. To imitate native 
biological scaffolds require that we should understand the natural role and structure of 
collagen in vivo. Specially, Collagen type I are widely used to prepare scaffold in 
tissue engineering. In designing different scaffold, the biological active groups have 
been modified on the culture surface or scaffold, such as RGD and galactose. 
 
In additional to the biomaterials for the cell culture and tissue engineering, some 
different cell containers, including macro-capsules, micro-capsules and hydrogel 
scaffold are used for hepatocytes culture in vitro and liver tissue engineering. In recent 
years, In situ formation gel scaffold are start to be focused on. The novel crosslinker 
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groups have also been studied for preparing cell culture scaffold, which can be 
applied in vitro and in vivo.  
 
Finally, we can develop strategies either for the engineering of living tissue substitutes 
or for the fostering of tissue repair or remodeling. Consequently, two suitable different 
culture systems have been designed in this thesis, basing on the modification of 
biomaterials, biological active chemicals and 3-D cell containers, which will be 
applied as in vitro device and implantable scaffolds in the area of liver tissue 
engineering.  
 
1. Collagen materials: Characterization and application 
Collagen family includes some different type collagens, which have different 
characters and functions in vivo. Only the fibrillar collagens are suitable to be used as 
the biomaterials for preparing scaffolds, which are due to the distribution in vivo and 
characters of collagen. Specially, The collagen type I is one of the most popular 
biomaterials for scaffold in vitro. 
1.1 Importance of ECM in cell culture 
The ECM includes fibrillar protein and polysaccharides, which are important to build 
a cell living environment in vivo. So understanding the characters of ECM is benefit 
to design a suitable cell culture environment in vitro.  
1.1.1 The concept of ECM 
The extra cellular matrix is a complex, dynamic and critical component of all tissues. 
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It functions as a scaffold for tissue morphogenesis, provides cues for cell proliferation 
and differentiation, promotes the maintenance of differentiated tissues and enhances 
the repair response after injury. Various amounts and types of collagens, adhesion 
molecules, proteoglycans, growth factors and cytokines or chemokines are present in 
the tissue- and temporal-specific extra cellular matrices. Biologically active extra 
cellular matrix components may have use in tissue repair, regeneration and 
engineering, and in programming stem cells for tissue replacement 
 
1.1.2 The important of ECM in cell proliferation and differentiation  
Most cells in multi-cellular organisms are in contact with an intricate meshwork of 
interacting extracellular collagens, proteoglycans and adhesion proteins, as well as 
growth factors, chemokines and cytokines. Together, these components constitute the 
extracellular matrix (ECM) [1]. Many ECM proteins form large families with some 
30 genes identified for collagens and 12 identified for laminins. Major recent 
advances have been made in the identification of new ECM molecules and in the 
determination of the domain structures and molecular organization of many 
components. The role of these components in development has also been defined and 
progress has been made in the identification of structurally and biologically active 
sites. The amount and type of these components vary considerably in different tissues 
and usually differ within the same tissue depending on the developmental stage.  
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ECMs not only provide support, tensile strength and scaffolding for tissues and cells, 
but also serve as three-dimensional substructures for cell adhesion and movement, as 
a storage depot for growth factors, chemokines and cytokines, and as signals for 
morphogenesis and differentiation. Liver ECM, which is highly enriched in some 
proteoglycans and collagen I, has an additional unique function in resisting 
compression. By contrast, basement membrane matrices, which are enriched in the 
glycoproteins laminin and entactin/nidogen and collagen IV with lesser amounts of 
proteoglycans and growth factors, regulate cell polarity, separate different tissue types. 
With the identification of many new ECM family members and elucidation of the 
atomic structures by X-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy [2]. Such approaches have begun to specify the intermolecular 
interactions important in ECM assembly and biological activity. [3] 
  
In general, the biological response involves multiple cellular interactions with 
individual ECM molecules and with multiple sites within the same molecule; the 
response is also influenced by the biomechanical properties of the ECM. Intracellular 
signaling pathways to affect the cellular response integrate multiple ECM signals 
transmitted via diverse surface receptors. The biological activity of the ECM has been 
studied in vitro using complex three-dimensional matrices (either cell- or tissue-
derived), gels of individual components (collagen or laminin), and proteolytic or 
recombinant fragments of ECM components or peptides. Three-dimensional matrices 
appear to mimic the in vivo functions of the ECM, and the function of individual 
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components has been further studied with synthetic peptides and recombinant 
fragments to identify targets for tissue engineering and repair [4, 5, and 6]. In our 
research, the modified collagen, which was conjugated by galactose group, was 
prepared for the suitable ECM in vitro. The microcapsule and scaffold are all 3-D 
culture system, which mimic the ECM environment in vivo.  
   
The biological responses to the ECM are regulated by specific cell-surface receptors 
[7]. Many different receptors have been identified that transduce signals to the 
cytoskeleton and nucleus, such as the galactose receptor on the surface of hepatocytes. 
[11, 12, 13] These include members of the heterodimeric integrins, receptor tyrosine 
kinases and phosphatases, immunoglobulin super family receptors, dystroglycan, and 
cell-surface proteoglycans. It is important to note that most of the biologically active 
ECM molecules, including laminins, collagens, thrombospondin and fibronectin, 
contain multiple active sites, often for different activities, and interact with different 
receptors. In our research, to enhance the cell functions of hepatocytes, the galactose 
group, which can interact with ASGPR on the surface of hepatocytes, was conjugate 
to the collagen, which  
The importance of ECM molecules in development has been proven by in vivo studies 
using gene targeting [8]. Mice lacking certain ECM component genes die before birth, 
whereas others survive and exhibit unique tissue phenotypes. The basement 
membrane, a critical ECM component during early development, is composed of the 
trimetric glycoprotein laminin, collagen IV, perlecan, entactin/nidogen, and various 
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growth factors [9, 10 and 11].  
The large number of ECM molecules and their interactions with each other define 
unique biological matrices important in morphogenesis [14]. There is considerable 
variation in the amount and type of specific components present in ECMs in different 
tissues and at different stages of development [15, 16]. Also, the specific laminin iso-
form in each of these tissues varies during development. In addition, there are 
different growth factors in each of these tissue ECMs. This review will focus on the 
role of the ECM in a few organ systems, but it should be noted that all cells are 
influenced by the ECM. Emphasis will be placed on the role of the basement 
membrane and its components, as this is an area of active discovery.  
1.2 Application of collagen  
1.2.1 Collagen materials: properties and availability  
Here, we use collagen type I as the matrix in our engineered matrix for the liver 
device culture system. First we show understand the characters of collagen. 
1.2.1.1 Characterization of collagen as biomaterials 
Collagen is the primary structural material of vertebrates and is the most abundant 
mammalian protein accounting for about 20–30% of total body proteins [17]. It is 
present in tissues of primarily mechanical function. About one half of the total body 
collagen is in the skin and about 70% of the material other than water presents in 
dermis of skin and tendon is collagen. Collagen made its appearance at the early stage 
of evolution in such primitive animals as jellyfish, coral and sea anemones [18]. 
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Collagen is synthesized by fibroblasts, which usually originate from pluripotential 
adventitial cells or reticulum cells. The molecular structure of collagen has been 
firmly established on the evidence from earlier studies, such as amino acid 
composition analysis, X-ray diffraction analysis, electron microscopy and 
physicochemical examination of solutions [19]. Collagen has a unique structure, size 
and amino acid sequence. [20] The collagen molecule consists of three polypeptide 
chains twined around one another as in a three-stranded rope. Each chain has an 
individual twist in the opposite directions. The principal feature that affects a helix 
formation is a high content of glycine and amino acid residues [21]. The strands are 
held together primarily by hydrogen bonds between adjacent -CO and -NH groups, 
but also by covalent bonds [22]. The basic collagen molecule is rod-shaped with a 
length and a width of about 3000 and 15 A, respectively, and has an approximate 
molecular weight of 300 kDa [23; 24]. 
At least 19 types of collagen have been reported. Types I, II and III collagen as well 
as types V and XI are built up of three chains and all are composed of the continuous 
triple-helical structure. Types I, II, III, and V are called as fibril forming collagens and 
have large sections of homologous sequences independent of species [25]. In type IV 
collagen (basement membrane), the regions with the triple helical conformation are 
interrupted with large non-helical domains as well as with the short non-helical 
peptide interruption. Fibril associated collagens (Type IX, XI, XII and XIV) have 
small chains, which contain some non-helical domains. Type VI is micro-fibrilla 
collagen and type VII is anchoring fibril collagens [26]. 
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An investigation on the native collagen has led to a better understanding of a structure 
function relationship between target drugs and collagen. A three-dimensional (3-D) 
model of fibril-forming human type II collagen was proposed for the development of 
synthetic collagen tissues and the study of the structural and functional aspects of 
collagen [27]. This system also allows the studies of the stereochemistry of all the 
side chain groups and specific atomic interactions, and further valuation of its 
therapeutic effects on collagen related diseases. The orderly arrangement of triple 
helix tropocollagen molecules results in a formation of fibrils having a distinct 
periodicity. Nonhelical telopeptides are attached to both ends of the molecule and 
serve as the major source of antigenecity. Atelocollagen, which is produced by 
elimination of the telopeptide moieties using pepsin, has demonstrated its potential as 
a drug carrier, especially for gene delivery [28, 29]. It has high tensile strength and 
high affinity with water. Moreover, it is nontoxic, biocompatible and biodegradable 
[30, 31]. It can be prepared in a number of different forms including strips, sheets, 
sponges and beads. Collagen can be solubilized into an aqueous solution, particularly 
in acidic aqueous media, and can be engineered to exhibit tailor-made properties. 
Collagen is relatively stable due to its function as the primary structural protein in the 
body, but it is still liable to collagenolytic degradation by enzymes, such as 
collagenase and telopeptide-cleaving enzymes [32]. Collagenase binds tightly to triple 
helices, and degrades collagen starting from the surface. The melting profile of the 
pepsin-solubilized collagen showed a biphasic transition, indicating that age-related 
decrease in thermal stability has implications for the mechanical strength and turnover 
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of the bone collagen [33]. 
Reports of adverse reactions to collagen have been restricted to localize redness and 
swelling following plastic surgery using collagen implants and wound breakdown 
with the use of catgut suture material [34, 35]. Clinical reactions to collagen were rare, 
but two cases of allergic (IgE-mediated) reactions to bovine collagen were reported 
[36]. Patients in both cases developed conjunctive edema in response to the topical 
application of highly purified bovine collagen to eye during ophthalmic surgery. 
When irritant effects and cytotoxicity of various products developed from collagen 
were evaluated, cell response to exogenous collagen starts shortly after the material is 
kept in contact with tissues, evoking a local and fast inflammatory response, whose 
intensity depends on the pharmaceutical formulation in use [37]. Even though, 
unknown reverse effects may be discovered in the future application of collagen for 
gene delivery or tissue engineering, since collagen can help to avoid side effects 
originated from incorporated drugs, therapeutic peptides and proteins, the need for the 
continuous effort in development and evaluation of collagen based systems is 
manifest.  
 
1.2.1.2 Fibrillar collagen 
Type I collagen protein has been studied and characterized for more than 50 years. 
Schmitt et al. [38 and 39] developed methods for isolating and purifying collagen in 
high yield from bovine skin, using the enzyme pepsin. This method is still preferred 
for obtaining a highly purified solubilized collagen, which under proper conditions 
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can yield medical grade soluble and fibrillar collagen, suitable for human implantation. 
In 1958, Gross and Kirk [40] showed that acidic solutions of collagen (at 0.2 to 2 
mg/ml) could be adjusted to physiological ionic strength and pH in the cold (less than 
10 °C), and then warmed to 30–34 °C for an hour, forming a translucent collagen gel, 
which is relatively firm, but friable under applied stress. (These are referred to as 
"heat gels", HG; see below for a discussion of flowability.) McPherson et al. [41] 
showed that pepsin-treated bovine collagen solution in acid at 3 mg/ml (referred to as 
AC) could be rapidly precipitated by mixing with a mixture of sodium phosphate and 
sodium hydroxide to effect a final pH of about 7 and a phosphate concentration of 20 
mM. The precipitate was harvested after centrifugation. Depending on the time and g 
force of centrifugation, one obtained fibrillar suspensions of 30- to 100-mg 
collagen/ml. Such fibrillar suspensions could then be mixed with additional sodium 
phosphate and sodium chloride to a final concentration of collagen of 30–40 mg/ml 
and a salt environment of 20 mM phosphate and 130–150 mM sodium chloride, pH 7 
(referred to as FCS). Blending and screening of the FCS was then performed to obtain 
a uniform, viscous paste which could be extruded through small gauge needles, in 
some cases easily flowing through needles 1 cm in length and approximately 150 m 
(30 gauge) inside diameter [42 and 43].  
In general, polymer gels consist of an interconnected network of polymer chains, 
reaching infinite molecular weight, plus accompanying solvent; the connections create 
the elastic character of the gel [44]. Gels in which the connections are not covalent 
(i.e., gels which are not cross-linked) can also have viscous properties, since, under 
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stress, the molecular chains can slide past each other [45]. FCS possess gel properties 
because they consist of entanglements of collagen fibers, which are quite variable in 
length and thickness, suspended in aqueous buffer [46, 47 and 48]. The fibers attract 
each other through hydrophobic and electrostatic bonds [46, 49 and 50]. Under flow 
conditions, such as stirring in a vessel with a paddle agitator, extrusion from a tube or 
syringe, or pumping through tubing, the fiber entanglements yield to the imposed 
stress and exhibit apparent shear-thinning behavior [51]; once the suspension is at rest, 
the fibers again entangle and exhibit gel-like behavior [48]. The behavior is 
temperature dependent, the gel being easily fluidized at 10 to 25 °C, but becoming 
relatively rigid after incubation at 30–37 °C [46]. The latter behavior is advantageous 
for delivery into warm-blooded animals, since the gel can be easily injected at room 
temperature, but after an hour in tissue it becomes more rigid, resisting displacement 
from the tissue site. In the case of injectable collagen fibers, the porosity of the gels is 
quite large, the "mesh size" being estimated to be several tens of nanometers [47，  
48]. In the case of HG collagen, the gel is so firm that imposed stress will "fracture" 
the gel and irreversibly dis-assemble the network connections [46 and 52]. 
 
1.2.1.3 Non-fibrillar collagen 
FCS can be dialyzed versus 0.01 M HCl (at 5–10 °C) to yield a viscous, transparent 
molecular collagen at about 20 mg/ml [53, 47, 48 and 52]. During dialysis, the bag 
swells, diluting the collagen from the original 30–40 mg/ml. Such highly viscous, 
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non-fibrillar solutions can be neutralized by adding sodium hydroxide, with stirring 
on ice, and monitoring the pH with indicator paper. If warmed, these transparent gels 
will slowly form fibers. Stabilized non-fibrillar collagen can be prepared by 
succinylation (referred to as SC) [54, 55 ] or methylation (referred to as MC) [54] of 
the collagen. Succinylated collagen has many of its lysine side chains converted to 
succinate esters. The molecule possesses a net negative charge at neutral pH. 
Methylated collagen is the reverse, in which aspartate and glutamate side chains have 
been modified to the methyl ester, thus removing carboxyl side chains; charged amino 
side chains remain, and the molecule has a net positive charge (see Scheme 1). These 
viscous, transparent gels do not convert to the fibrillar state at neutral pH because of 
charge repulsion. They are gels because the rod-like collagen molecules are entangled. 
The molecules are much thinner than fibers, and the resulting porosity, or "mesh" of 
the gel is finer, about 4 to 30 nm, depending on concentration and additives [48 and 
56]. Since the gels are true solutions of collagen in aqueous media, they also are 
injectable through fine-gauge needles. The injection force is higher, compared to 
fibrillar collagen at the same concentration (unpublished measurements, Collagen).  
1.2.2 Collagen materials in tissue engineering application 
The collagen has been widely used in the area of tissue engineering. The collagen type 
I and mixture of different type collagen are popular natural biomaterials for building 
scaffolds and hydrogels. 
1.2.2.1 Implant fabrication and cell culture 
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As early as 1962, Grillo and Gross [57] described the preparation of collagen gels 
from neutralized acidic collagen solutions, and proposed their use as medical implants. 
They showed that gels, sheets, tubes and various articles could be prepared, and they 
formed gels in animal tissue by injecting cold neutralized collagen solutions. They 
also studied the immunological reactivity of bovine collagen (without pepsin 
treatment) in other vertebrate species, demonstrating the relative safety of collagen 
implants. Collagen gels for culture of living cells in vitro came into wide use (see, for 
example, [58]). Stopak et al. [59] showed that collagen gels formed after injection in 
developing chick limb buds re-arranged to conform with the host tissue, and formed 
parts of tendon and other structures. Such work set the stage for the use of collagen 
gels plus living cells, capable of being remodeled to generate new functional tissue. 
One of the earliest collagen tissue engineering applications was the development of an 
artificial skin for treatment of burns [60], which was a membrane, and not a collagen 
gel. Below are presented further examples of the use of collagen gels. The list is not 
exhaustive; more references could be cited, using much the same methods. 
 
Scheme. 1. Collagen species of interest. (A) Collagen fibrils in neutral aqueous buffer. 
(B) Collagen molecules in solution; cold, neutral pH. (C) Methylated collagen with 
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charged amino groups displayed (neutral pH). (D) Succinylated collagen with charged 
carboxyl groups displayed (neutral pH). (E) Collagen molecule tethered through a 
flexible polymer chain (such as PEG) to an active agent (black circle). 
 
1.2.2.2 Example of simple constructed tissues utilizing collagen gels 
Wakitani et al. [61] embedded chondrocytes in collagen gels to repair articular 
cartilage defects. Acidic collagen at 3 mg/ml was neutralized by adding 100 ml 2× 
concentrated DMEM to 100 ml of collagen solution at 4 °C. Chondrocytes were 
added as a pellet (1×106 cells), the mixture was gelled in an incubator at 37 °C for 10 
min or more, and then implanted in cartilage defects in rabbits. The chondrocytes 
maintained their phenotype and new cartilage was observed as early as 4 weeks. The 
grafted tissue remained as cartilage over 48 weeks.  
Orwin and Hubel [62] attempted to construct corneal tissue, using epithelial, 
endothelial, and keratocyte cells plus collagen sponges. They cited an earlier study in 
which collagen gels were tried for this application [63], but the implants lost 
transparency, due to extreme contraction of the collagen gel by keratocytes. To 
overcome the contraction, Orwin and Hubel resorted to a collagen sponge, which was 
sufficiently rigid to resist cellular contraction forces. To achieve translucency of the 
sponge, they prepared a dispersion of collagen in dilute acid, pH 4, followed by 
freeze-drying. Such acid-swollen collagen should have less fibrillar structure (thinner 
fibrils) and should scatter less light than fibrils formed at neutral pH.  
Awad et al. [64] incorporated autologous mesenchymal stem cells into collagen gels 
for tendon repair. In order to avoid problems of gel contraction in vivo, they incubated 
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cells and gel for 18 h prior to implantation; this approach allowed contraction to occur 
before insertion into the tissue site. In the tendon defect, the stem cells differentiated 
into tenocytes. Compared to controls (collagen gels with no cells), the stem-
cell/collagen gels yielded repaired tendons with improved mechanical properties. The 
authors expressed an interest in having collagen matrices with aligned fibers. In the 
typical heat gel (HG), collagen fibers are randomly oriented.  
Another approach to the problem of collagen gel contraction was the study of 
Moriyama et al. [65], in which a collagen gel plus cells was cast into a pre-formed 
collagen sponge. The sponge provided rigidity. Nevertheless, within the sponge pores, 
it was observed that the gel elements did contract. Such matrices were prepared with 
fibroblasts in the collagen gel phase, but later keratinocytes were cultured on one 
surface of the gel, to simulate oral mucosa. The tissue constructs were implanted onto 
skin wounds in nude mice. The grafts epithelialized and exhibited limited wound 
contraction, compared to wounds with no grafts. 
 
1.2.2.3 Enhancing functionality 
The examples below utilize multiple constituents to construct tissues, including 
stratagems to strengthen the gel, and achieve adhesion of components. The followings 
are all important part to form the artificial liver in vitro and in vivo. 
1.2.2.3.1 Artificial myocardial tissue 
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Myocardial infarction damages regions of heart tissue, leading to patient morbidity 
and mortality. Engineering and transplantation of artificial myocardial tissue to 
replace ischemic and infarcted areas of the heart is an alternative to whole organ 
transplantation [66]. Kofidis et al. [66] described the production of collagen devices 
colonized with cardiomyocytes that showed continuous, rhythmic, and synchronized 
contractions for up to 13 weeks in vitro. Such devices are close to possessing the 
properties necessary for repair of the heart, which include uniform colonization of the 
implant with viable cells, and adequate mechanical strength for manipulation in 
surgery. To form the constructs, 1 ml of cell suspension in soluble collagen containing 
2×106 cells was added to a sheet of collagen fleece and gelled for 4 h at 37 °C. Strips 
of the tissue construct could be cut, mounted with cyanoacrylate glue to metal holding 
bars, and subjected to electrical stimulation. One of the bars was connected to a force 
transducer to measure contractile forces. Stretching forces could also be applied to the 
artificial tissue. Electrocardiograms of the constructs could also be monitored, after 
placement of electrodes in the strips. The whole system was immersed in culture 
medium in which physiologic oxygen and carbon dioxide levels were maintained by 
an external supply. A similar experimental system was described in detail in an earlier 
publication [67], in which the collagen gel was anchored to test bars through Velcro, 
as an alternative to glueing with cyanoacrylate. The filaments of the Velcro were 
embedded in the cast gel. The cells contracted the rectangular gel to a bi-concave 
shape . The gel formed a net-like, coordinately beating heart-like tissue. Such tissue 
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constructs showed electrocardiogram patterns and responded to drug and mechanical 
stimuli in a fashion similar to normal heart tissue [66 and 67].  
1.2.2.3.2. Small diameter vascular grafts 
There have been several different approaches to the fabrication of vascular grafts, 
including use of de-cellularized tissues, synthetic polymer tubes seeded with cells, 
sheets of cells plus cell-synthesized extra-cellular matrix, and finally reconstituted 
collagen gels, formed with and compacted by cells [68]. To be successful as 
replacement grafts, artificial constructs need to possess adequate burst strength to 
withstand blood pressure and sufficient compliance match with native arteries, 
including elasticity without creep. Early constructs contained smooth muscle cells and 
fibroblasts in a collagen gel, seeded on the surface with endothelial cells. The 
collagen gel possessed inadequate strength to sustain arterial pressures, and it was 
reinforced with a Dacron™ sleeve [69, 70]. Later versions were prepared by casting 
the cell-seeded collagen gel around a mandrel. During subsequent culture, cell-
generated  
1.2.2.3.4 Hepatocyte culture 
Natural collagenous extracellular matrix (ECM) scaffolds such as small intestine 
submucosa (SIS) and chemically or physically decellularized matrices have been 
utilized in many studies of tissue reconstruction for vessels, nerves, intestines and 
urinary tracts [71]. However, there is no evidence that such growth factors uniformly 
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remain on every SIS at the optimal dose, which may be a reason of uneven healing 
effect observed in the clinical and experimental applications. Therefore, it is 
necessary to investigate the use of growth factor activity in more controllable manner.  
Since the bioactivity of growth factor protein cannot always be expected in the 
solution form, an effective delivery system is required when they are used for 
therapeutic use. In this regard, the natural ECM system has been an ideal model for 
such system [72, 73,]. 
  
1.2.2.4 Improve gel strength 
Although collagen gels are widely used in tissue engineering [69], the nature of their 
application has changed little in more than a decade. Despite their advantages of 
convenience and biocompatibility, they have limitations. The chief drawback, as 
mentioned above, is the inability to control final gel properties beyond a relatively 
narrow range. Randomly oriented gels are too weak for surgical manipulation or to 
bear tensile loads in vivo [71].  
One way to improve gel strength is with various composite forms, in which collagen 
gels are combined with solid form collagen articles, such as sponges [65], sheets [60], 
and pre-formed fibers [74]. Another is to devise some means to align growing 
collagen fibrils and cells. [67] above describes casting the cells and gel so that the 
ends of the gel are anchored in Velcro and attached to metal bars. Such a gel could be 
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cast, detached from its mold and allowed to incubate for a few days with no tension 
applied. This would permit gel contraction by the cells, which reduces the volume 
(raising the collagen concentration to about 4 mg/ml and aligning the collagen fibers 
to some extent). Using the attached metal bars, the gel plus cells could then be 
mounted in a device which would apply cyclic loading to the gel. The device would 
be analogous to that of Eschenhagen et al. [67]; it would not only measure contractile 
force, but also apply force. Based on the results of Seliktar et al. [75], one would 
anticipate that cyclic loading in culture, including increased deformation of the 
construct, would promote even more alignment of cells and collagen fibers, enhancing 
the strength of the construct, as much as three-fold . The final gel could have better 
overall mechanical properties, especially when subject to stretching, than a gel 
reinforced with a collagen sponge or collagen fleece.  
Simply preparing the gel with higher concentrations of collagen probably will inhibit 
movement of cells and nutrients, while providing only modest increases in strength. 
Gels formed from FC (20–60 mg/ml), while biocompatible and injectable, are easily 
broken (friable) [46]. In addition, they are dense and form a barrier for cell movement 
[42]. In vivo, FC gels condense to higher collagen concentrations and are poorly 
penetrated by surrounding fibroblasts or other cells [42]. The use of cross-linkers or 
reactive polymers added to FC, soluble collagen, or collagen gels, although they can 
improve mechanical strength, will reduce porosity (limit cell movement), and may 
have other negative influences on cells. Reactive polymers can, however, be useful in 
bonding constructed tissues together [75]. Rhee et al. [75] have described an adhesive 
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prepared from di-succinimidyl PEG and methylated collagen (MC), which was useful 
for attaching an in situ polymerizable lenticule to bovine cornea. 
After understanding the characters of collagen and application in biology, there is no 
previous study about the collagen modification with biological active groups by 
chemical method. On the other hand, we have created a novel galactocylated collagen 
basing on the cell culture principle of biological active groups and protein supporter 
in vitro. 
1.3. Collagen as bioengineered tissues 
Collagen gel as human skin substitutes have demonstrated its usefulness in tissue 
engineering and led to the development of bioengineered tissues, such as blood 
vessels, heart valves and ligaments [76]. Collagen shows hemostatic properties that 
promote blood coagulation and play an important role in tissue repair process. 
Collagen sponge or gel initiates adhesion and aggregation of platelets that lead to a 
thrombus formation [ 20]. Monomeric collagen does not activate platelet aggregation, 
while polymeric collagen having a regular arrangement of the molecules with a length 
of around 1 m does activate it. Arginine side chains of collagen seemed to be 
responsible for its interaction with platelets [ 77].  
A provisional extracellular support was developed using type I collagen lattice to 
organize the cells into a three-dimensional structure in vitro [78]. A small-diameter (4 
mm) graft constructed from type I bovine collagen was earlier used to integrate into 
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the host tissue and provide a scaffold for remodeling into a functional blood vessel 
[ 79]. Three-dimensional collagen scaffolds, that are biodegradable in vivo and have a 
large surface area for cell attachment, can support vascularization processes and can 
be used as artificial blood vessels, heart valves or cell transplant devices [80 ，81]. 
The use of collagen as a coated material for permeation filters made of culture 
endothelial cell monolayers was also tested to evaluate in vitro vascular permeability 
of a drug to contrast media [ 81].  
A method for generating a cellular layer of intestinal collagen from the porcine 
submucosa without compromising the native collagen structure further facilitated the 
use of collagen in tissue engineering [82]. Biological tissue grafts in the form of 
collagen-based matrix have been derived from bladder, ureter or small intestine [83]. 
These collagen constructs were designed to be similar to synthetic polymer prostheses 
in terms of their ability to persist. The structure-mechanical behavior relationship of 
biomaterials acquired from intestine submucosa demonstrated mechanical anisotropy 
and stiffer direction preferred in biomaterials [84]. Using a phenomenological 
constitutive model, it was demonstrated that glycan increased the tensile stiffness and 
ultimate tensile strength of collagen-based matrix and further increased their 
resistance to collagen degradation.  
Natural collagenous materials were used for surgical repair and abdominal wall repair 
by taking advantage of their inherent low antigenecity and their ability to integrate 
with surrounding tissues [85]. Moreover, new generations of collagen-based 
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biological tissue are practical and remodelable due to its simple membranous 
configuration, relative uniformity and abundant availability. These characteristics are 
employed in a new type of surgical adhesive made from porcine collagen and 
polyglutamic acid, developing for sealing air leaking from the lung, which takes a 
relatively long period for recovery [86]. The absorption rate of collagen-based 
adhesive can be controlled by collagen concentration in the system. Recent progress 
in tissue engineering may lead to well-characterized and reproducible biomaterials 
from natural collagenous materials. 
From the previous applications of collagen in bioengineering, we prefer to chose 
collagen type I as the biomaterials for liver tissue engineering. In our study, the 
microcapsules and in situ gelation scaffold were created as the formation of cell 
containers in vitro. 
2. The application of galactose in tissue engineering 
In our research, the galactose group is another key point. The receptors on the surface 
of hepatocytes are widely applied in enhancing adhesion of cells and functions of 
hepatocytes in scaffold.   
 
2.1 The principle of galactose group for the liver tissue engineering 
Galactosylated substrate is an attractive alternative to collagen because of the specific 
interaction of cell surface asialoglycoprotein receptor (ASGPR) in hepatocytes with 
the galactose moiety [87]. Lactose-carrying polystyrene (PLVA) substrates have been 
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shown by Akaike et al. to induce selective adhesion of hepatocytes and cells, which 
subsequently exhibited aggregated morphology and maintained good level of cellular 
functions [88 and 89]. Gutsche et al. showed similar results using a galactose-derived 
polystyrene porous network [90]. In a hydrogel configuration, Griffith et al. also 
showed that a galactose-conjugated poly(ethylene oxide) hydrogel could promote 
hepatocyte attachment and functional maintenance [91 and 92]. 
 
2.2 The application of galactosylated biomaterials in liver tissue engineering 
Basing on the interaction of galactose group and the asialoglycoprotein receptor 
(ASGPR) at cell-substrate interface, the galactose group have been conjugated to the 
materials to mediate hepatocytes adhesion and maintain liver special function of 
hepatocytes. Some studies showed that the glacatosylated surface can enhance the 
adhesion of hepatocytes [92]. On the other hand, other shows that the galactosylated 
PET surface can induce the formation of spheroids and also maintains the liver special 
functions of hepatocytes. [93] The galactosylated chitosan was also been synthesized 
as the 2-D extracellular matrix. The galactose-carrying gelatin sponge was evaluated 
as a kind of 3-D ECM for hepatocytes culture. [94] The liver special functions of 
hepatocytes which were encapsulated in Ba-alginate capsules with galactosylated 
chitosan and PVA have been evaluated too. [95] So the galatose group which was 
conjugated to the different materials can enhance the cell seeding efficiency and cell 
functions in vitro.  
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3. The cell encapsulation system in tissue engineering 
The collagen and galactose group were used as biomaterials in our culture system. 
However, the biomaterials can be prepared to different formations, such as 
microcapsules, scaffold, and hydrogel. The microcapsules systems have higher 
surface/volume ratio, which can mimic the liver structure in vivo. On the other hand, 
the microcapsule is also an immuno-isolation system, which can protect cells from 
attack of antibody. 
3.1 The technology of cell encapsulation 
3.1.1 Macroencapsulation 
Macrocapsules are generally much larger devices compared to microcapsules and typically 
possess a planar or cylindrical geometry, and a smaller surface-to-volume ratio. Living cells are 
physically isolated from directly interacting with host tissue by enclosure between two or more 
selectively permeable flat sheet membranes or within the lumen of a semi permeable hollow fiber. 
Like their smaller counterparts, these devices rely on the host animal’s own homeostatic 
mechanisms for the control of pH, metabolic waste removal, electrolytes, and nutrients. 
Concentration gradients are used to transfer solutes across the encapsulation membrane that in 
general confers progressively greater resistance to the diffusive transport of molecules as the 
encapsulation device increases in size. Unlike the hydrogel membranes of microcapsules, the 
membranes of macrocapsules are typically composed of thermoplastic materials that vary in their 
structural, functional, and mechanical properties. At least two general categories of 
macroencapsulation implants can be distinguished based on their association with host vasculature. 
Intravascular devices are connected or anastomosed directly to existing host vasculature, while 
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extravascular devices rely on the formation of new blood vessels at the host–device interface 
following implantation to sustain the viability of the encapsulated cell mass.  
The macrocapsulation approach was originally developed as a basic research tool to 
understand fundamental issues of immunology and transplantation biology, and is 
now being developed as a therapeutic device to treat endocrine, metabolic and 
nervous system disorders [96, 97 and 98]. As basic research tool, the key functional 
attribute is physical isolation or containment of the transplanted cells or tissue within 
a selectively permeable membrane. The fact that macroencapsulated cells can be kept 
alive for prolonged periods following implantation into a variety of tissues and body 
cavities while being physically isolated from interacting directly with host cells, 
vasculature, certain size classes of solutes, and the extracellular matrix of host tissues 
has led to a number of important discoveries in developmental biology, immunology 
and neuroscience. Although a handful of studies have been performed in amphibians 
[99] and birds [100, 101 and 102], the majority of studies have utilized mammalian 
species. As a therapy, macroencapsulation technology is being developed as a 
sustained delivery system to provide biologically active agents with a wide range of 
pharmacological profiles to treat conditions where improvement may be obtained by 
continuous delivery of a therapeutic substance either system or in a site-specific 
manner. In addition, the macroencapsulation approach is being developed as an 
implantable homeostatic sensor-release system where the implant responds to changes 
in solute concentrations of the extracellular space by releasing substances to function 
in an endocrine or metabolic capacity.  
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Over the past 50 years, the technology of macroencapsulation has advanced from a 
simple laboratory tool to a promising bedside therapy [98, 103 and 104]. Several 
human clinical trials have been conducted or are underway [98, 105 and 106]. 
Numerous companies have been founded in attempts to develop the immense 
commercial potential that this technology promises. To deal with the many challenges 
of clinical application, the technology has evolved from simple designs involving one 
to three components to sophisticated multi-component assemblies. Issues related to 
mass production, safety, and long-term clinical utility have fueled the development of 
a more sophisticated generation of devices. Technological improvements have taken 
place in all facets of the technology including: novel device configurations; 
membrane coatings; core matrix development; retrievable and refillable designs; cell 
engineering; and surgical technique. 
3.1.2 Microencapsulation 
Capsules in the 0.3–1.5 mm range have been traditionally refereed to as 
microcapsules in the cell encapsulation field. Their relatively small size (i.e., large 
surface area to volume ratio) is considered advantageous from a mass transport 
perspective. Microcapsules are typically more durable than macrocapsules and 
difficult to mechanically disrupt. Numerous microencapsulation techniques, 
fundamentally different in the nature of entrapment mechanism, were developed in 
independent labs. Besides traditional capsules with a well-defined shell-and-core 
structure, encapsulation in microbeads without a distinct membrane has been 
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successful for certain applications. The homogenous bead milieu is entrusted to 
provide the desired permeability barrier in this case. ‘Conformal’ coating where the 
surface of a cell mass is surrounded with a membrane has also been attempted to 
minimize the internal mass transfer resistance. Irrespective of the entrapment 
geometry, a gentle entrapment process is vital for fragile cells incapable of 
proliferation or of exhibiting a robust regeneration. Relatively mild conditions (e.g., 
processes carried out in aqueous conditions without the use of reactive species), 
however, generally yield a less durable microcapsule. Harsher encapsulation 
conditions might compromise cell viability but the resultant capsule may be more 
resilient and cells capable of proliferation may be suitable for such conditions. Fragile 
cells can also be subjected to harsher conditions provided that the cells are 
compartmentalized from toxic chemicals or conditions. All techniques typically start 
with a scheme to generate a controlled-size droplet, followed by an interfacial process 
to stabilize the droplet and obtain a solid microcapsule membrane around the droplet. 
The intricacies in the initial droplet generation may make a significant difference in 
the success of encapsulation.[107,108] 
Microcapsules are almost exclusively produced from hydrogels since they hold a 
number of appealing features. Firstly, the mechanical or frictional irritation to 
surrounding tissue is reduced by the soft and pliable features of the gel. Secondly, as 
the consequence of the hydrophilic properties of the material, there is virtually no 
interfacial tension with surrounding fluids and tissues which minimizes the protein 
adsorption and cell adhesion. Combinations of these two factors result in high 
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biocompatibility. Thirdly, hydrogels provide a high degree of permeability for low-
molecular-mass (Mr) nutrients and metabolites. The complexation of polyanionic 
alginate with polycationic poly( -lysine) (PLL), initially developed by Lim and Sun 
[109], has been the first process utilized for cell microencapsulation. This is a gentle, 
cell-compatible process and is commonly credited for providing the impetus for the 
cell encapsulation field. The last two decades have seen adaptation of the initial 
technique by independent laboratories that naturally led to process improvements and 
development of superior encapsulation materials. Other techniques have since been 
attempted, primarily to overcome certain physicochemical limitations of the alginate–
PLL capsules.  
3.1.3 Other encapsulation technology 
A variety of entrapment techniques have been developed to overcome various 
shortcomings of the micro- and macroencapsulation. A silica sol–gel technique has 
been successfully used to entrap islets in ceramic membranes [110]. This is the first 
report on the encapsulation of mammalian cells in ceramic membranes.  
Thermosensitive, poly(N-isopropylacrylamide) (NiPAM)-based polymers have been 
utilized to entrap mammalian cells in a gelled medium [111]. The polymers exhibit a 
temperature-dependent solubility that is analogues to the solubility behavior of 
agarose: soluble at a relatively low temperature but insoluble beyond a certain 
temperature limit, so called lower critical solution temperature (LCST). Unlike 
agarose, the polymers can be conveniently engineered for desired properties, such as 
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LCST. NiPAM as a homopolymer does not undergo gelation when heated beyond its 
LCST (~30°C in water) and functional polymers for cell entrapment has been 
obtained by incorporating hydrophobic butyl methacrylate to the polymer backbone 
[111]. To augment gel stability, amine-reactive N-acryloxysuccinimide groups [112], 
or thiol groups capable of undergoing disulfide formation [113] have been 
incorporated into the polymer backbone. The gels can be crosslinked with diamino-
poly(ethylene glycol) in the former case without affecting the cell viability. Although 
immunoisolation by NiPAM-based gels remains to be reported, there is no 
impediment to further engineer the polymer or gel properties for this purpose [113].  
Unlike physical isolation barriers, Pollack et al. have developed a biological 
mechanism to prevent tissue reaction by utilizing the immune privileged properties of 
a chondrogenic environment [114,115]. This concept is analogous to previous 
observations where testicular cells co-transplanted with a graft was shown to provide 
a mechanism of immune suppression [116, 117]. Unlike membrane-based devices, a 
co-transplanted immune suppressive tissue mediates its effect by insoluble and/or 
soluble molecules derived from the tissue. It will be beneficial to identify the 
biological factors contributing to the immune suppression. However, if a single factor 
is found responsible for a broad immune suppression (rather than a cocktail of 
mediators), it might be feasible to incorporate the delivery of such a factor into the 
conventional membrane-based devices to attain a ‘bioartificial’ mechanism of 
immune suppression. 
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In our research, the coacervation of the modified collagen and the polymer was used 
to form the microcapsules. During the formation of microcapsules, the positive 
charged collagen neutralizes the negative charged polymer to form the undissolvable 
complex. In this kind of microcapsule, the core of microcapsule is modified collagen; 
while the shell of microcapsule is the complex of the polymer and the modified 
collagen.   
3.2 The application of microcapsulation system for immunoisolated 
transplantation 
3.2.1 The matrix properties for the cell proliferation and functionality 
3.2.1.1. Hydrogel and hydrocolloid-based encapsulation matrices 
Traditionally, matrices used in cell encapsulation devices to immobilize cells have 
been naturally-derived hydrogels [118]. Collagens comprise the most substantial 
component of natural extracellular matrix and have been widely used to simulate 
natural ECM in culture and as an encapsulated cell matrix. Collagen may take several 
forms including soluble collagen hydrogels (e.g, Vitrogen 100: Celtrix Laboratories, 
Palo Alto, CA), collagen sponges, or fibrillar collagen crosslinked with 
glutaraldehyde. Collagen hydrogel has been widely used in the artificial liver area to 
entrap hepatocytes within hollow fibers [119, 120] and in microcapsules [121]. 
Hepatocyte function has been found to be preserved in the 3-D collagen sandwich 
conformation whereas cells cultured in a monolayer rapidly lose their functionality 
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[122]. Collagen has also been used as a matrix for baby hamster kidney cells 
engineered to secrete NGF for the treatment of Alzheimer's disease [123].  
Matrigel® (Collaborative Research, Bedford, MA), a mouse sarcoma-derived 
extracellular matrix complex has been employed as a substitute for hepatocytes and 
other cell lines [118] and shown to improve long-term viability in microcapsules 
[121].  
Calcium crosslinked alginate has been used successfully as a matrix in hollow fiber 
membrane devices to immobilize bovine adrenal chromaffin cells used in the 
treatment of chronic pain [118]. In these devices, the chromaffin cells are aseptically 
suspended in 2% sterile alginate solution (Protan Biopolymer; Drammen, Norway). 
As in all cell-contacting polymer solutions, the alginate solution must be brought to 
physiological isotonicity and pH prior to combining with cells. The cell-alginate 
suspension is then injected into the lumens of hollow fiber pre-assembly devices. The 
end of the hollow fiber device may be sealed with a light-cured adhesive, heat-pinch 
closed or dipped into a PAN-PVC/DMSO solution. The implant is then immersed in a 
1% CaCl2 bath for five minutes to crosslink the alginate and immobilized the cells in 
the lumen. Alginate has also been used to suspend islets cells for diabetes treatment 
[124].  
Chitosan is a natural polysaccharide comprised of glucosamine monomers derived 
from chitin. Commercially available chitosan is produced by partial deacetylation of 
chitin obtained from shrimp and crab exoskeletons [125]. Chitosan is soluble in 
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weakly acidic solutions (below pH 6.3) – above pH 6.3 it precipitates out of solution. 
The positively-charged chitosan solution may be crosslinked with negatively-charged 
ions to form a hydrogel. Crosslinked chitosan has a history as a biomaterial in the 
areas of wound healing [126], plastic surgery and dental implants [127]. Crosslinked 
chitosan has been used successfully to immobilize plant and microbial cells [128, 
129]; however, attempts at immobilizing mammalian cells have not been particularly 
successful since they are more pH-sensitive in the acidic pH range that chitosan 
remains soluble [130]. Precipitated chitosan however has been demonstrated to 
promote mammalian cell viability and functionality as a matrix material. PC-12 rat 
pheochromocytoma cells immobilized in hollow fibers with precipitated chitosan 
(Protan Biopolymer; Drammen, Norway) have shown very good functionality 
compared to the same cells encapsulated without a matrix or with crosslinked chitosan 
matrix [130, 131, 132, 133]. The chitosan may be precipitated prior to cell contact by 
mixing with physiologic buffer or precipitated post-encapsulation by incubating the 
capsules in physiologic saline at pH 7.4. PC-12 cells have been widely investigated as 
a treatment for Parkinson's Disease since they naturally secrete the dopamine deficient 
in this disease state.  
The microcapsules were made form methylated collagen and Poly (HEMA-MAA-
MMA) by coacervation principle.(134) The hepatocytes were encapsulated in this 
kind of hepatocytes. Cell functions of hepatocytes were enhanced in this system 
compared to 2-D culture on culture plate coated by native collagen.(ref). The research 
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showed that the 3-D culture environment is better for hepatocytes cultured in vitro. 
This collagen microcapsule was also used as the container for cryopreservation.[135] 
3.2.1.2. Synthetic encapsulation matrices 
Recently a new class of synthetic scaffolds based on poly(vinyl alcohol) (PVA) foam 
has been introduced as a matrix for encapsulated cell devices [136]. The use of 
synthetic foam has many potential advantages over the traditional hydrogel or 
hydrocolloid matrix. These advantages include provision of a physical surface onto 
which adherent cells can lay their own extracellular matrix; growth control of contact-
inhibited cells; improved intracapsular nutrient transport through porous 
interconnecting channels; and lastly, limited cell cluster size to a maximum of the 
foam pore size – thus very large clusters with a tendency towards formation of a 
necrotic center are eliminated. The ability to control proliferation of cell lines is 
highly advantageous for cell encapsulation devices since maintenance of a stable cell 
number generally connotes delivery of a more consistent and predictable dose of the 
therapeutic factor [137, 138]. A stable cell number also improves long-term 
ncapsulated viability since buildup of antigenic debris due to cell turnover is lessened.  
3.2.2 Enhanced functionality of hepatocytes in the microcapsules formed by the collagen-
terpolymer system 
Previous study showed that cell functions of hepatocytes in microcapsules formed by 
the methylated collagen and Poly (HEMA-MAA-MMA) can be enhanced (205). The 
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cell functions of hepatocytes were much higher than those of hepatocytes cultured on 
the 2-D collagen gel. The other research about effects of molecular weight of 
copolymer to the cell functions of hepatocytes have also be studied [134]. The multi-
layer microcapsules [139] and photo-crosslinked [140] microcapsule membrane have 
been designed to enhance the mechanical characters of microcapsules.  
4. The hydrogel for tissue engineering  
An exciting approach to cell delivery for tissue engineering is the use of polymers (i.e., 
hydrogels) that can be injected into the body. This approach enables the clinician to 
transplant the cell and polymer combination in a minimally invasive manner. 
Hydrogels have structural similarity to the macromolecular-based components in the 
body and are considered biocompatible. [141] Hydrogels have found numerous 
applications in tissue engineering as well as in drug delivery. Tissue engineering is a 
most recent application of hydrogels, in which they are used as scaffolds to engineer 
new tissues. 
The field of tissue engineering has developed to meet the tremendous need for organs 
and tissues [142]. In the most general sense, tissue engineering seeks to fabricate, 
living replacement parts for the body.  
Numerous strategies currently used to engineer tissues depend on employing a 
material scaffold. These scaffolds serve as a synthetic extracellular matrix (ECM) to 
organize cells into a three-dimensional architecture and to present stimuli, which 
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direct the growth and formation of a desired tissue [143]. Depending on the tissue of 
interest and the specific application, the required scaffold material and its properties 
will be quite different. Common scaffold materials include poly (lactide-co-glycolide) 
(PLG). However, they are hydrophobic and typically processed under relatively 
severe conditions, which make factor incorporation and entrapment of viable cells 
potentially a challenge. As an alternative, a variety of hydrogels, a class of highly 
hydrated polymer materials (water content 30% by weight) [142], are being 
employed as scaffold materials. They are composed of hydrophilic polymer chains, 
which are either synthetic or natural in origin. The structural integrity of hydrogels 
depends on crosslinks formed between polymer chains via various chemical bonds 
and physical interactions. Hydrogels used in these applications are typically 
degradable, can be processed under relatively mild conditions, have mechanical and 
structural properties similar to many tissues and the ECM, and can be delivered in a 
minimally invasive manner.  
This review will focus on the use of hydrogels as scaffolds for tissues engineering. 
Adequate scaffold design and material selection for each specific application depend 
on several variables, including physical properties (e.g. mechanics, degradation, gel 
formation), mass transport properties (e.g. diffusion), and biological properties (e.g. 
cell adhesion and signaling). We have identified three categories of scaffolds 
applications in this review: space filling agents, bioactive molecule delivery, and 
cell/tissue delivery. The materials available for use in hydrogel formation are first 
discussed along with a description of the pertinent design variables.  
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4.1 Hydrogel from natural polymers 
4.1.1 Collagen and gelatin 
Collagen is the most widely used tissue-derived natural polymer, and it is a main 
component of extracellular matrices of mammalian tissues including skin, bone, 
cartilage, tendon, and ligament. Physically formed collagen gels are thermally 
reversible and offer a limited range of mechanical properties. Chemical cross-linking 
of collagen using glutaraldehyde [144] or diphenylphosphoryl azide[145] can improve 
the physical properties. However, these gels are still short of physical strength, 
potentially immunogenic, and can be expensive.[146] Furthermore, there can be big 
variations between produced collagen batches. However, collagen meets many of the 
biological design parameters, as it is composed of specific combinations of amino 
acid sequences that are recognized by cells and degraded by enzymes secreted from 
the cells (i.e., collagenase). Collagen has been used as a tissue culture scaffold or 
artificial skin due to the ready attachment of many different cell types and its cell-
based degradation. The attachment of cells to collagen can be altered by chemical 
modification, including the incorporation of fibronectin, chondroitin sulfate, or low 
levels of hyaluronic acid into the collagen matrix.[147] Collagen gels have been 
utilized for reconstruction of liver,[148] skin, [149] blood vessel,[150] and small 
intestine.[151]  
Gelatin is a derivative of collagen, formed by breaking the natural triple-helix 
structure of collagen into single-strand molecules. There are two types of gelatin, 
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gelatin A and gelatin B. Gelatin A is prepared by acidic treatment before thermal 
denaturation, while gelatin B is processed by alkaline treatment that leads to a high 
carboxylic content.[152] Gelatin easily forms gels by changing the temperature of its 
solution. It has been used in many tissue engineering applications due to its 
biocompatibility and ease of gelation. Gelatin gels have also been utilized for delivery 
of growth factors to promote vascularization of engineered new tissue.[153] However, 
the weakness of the gels has been a problem, and a number of chemical modification 
methods have been investigated to improve the mechanical properties of gelatin gels. 
4.1.2 Fibrin 
Fibrin has been used as a sealant and an adhesive in surgery as it plays an important 
role in natural wound healing. Fibrin gels can be produced from the patient's own 
blood and can be used as an autologous scaffold for tissue engineering. No toxic 
degradation or inflammatory reactions are expected from this natural component of 
the body. Fibrin forms gels by the enzymatic polymerization of fibrinogen at room 
temperature in the presence of thrombin.[154] An interesting feature of fibrin is the 
degradation and remodeling by cell-associated enzymatic activity during cell 
migration and wound healing, and its degradation rate can be controlled by apronitin, 
a proteinase inhibitor.[155]  
Fibrin gels might promote cell migration, proliferation, and matrix synthesis through 
the incorporation of platelet-derived growth factors and transforming growth 
factor.[156] Bidomain peptides with a factor XIIIa substrate in one domain and a 
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bioactive peptide containing RGD sequence in another domain have been covalently 
incorporated into fibrin gels during coagulation through the action of the 
transglutaminase factor XIIIa, resulting in gels with potential neurological 
applications.[157] Fibrin gels have also been utilized to engineer tissues with skeletal 
muscle cells, smooth muscle cells, [158] and chondrocytes.[159] However, fibrin gels 
are limited in mechanical strength, and this prevents their use in certain applications 
 
4.2 hydrogel from Synthetic polymers 
4.2.1 Poly (acrylic acid) and its derivatives 
One of the most studied synthetic hydrogels is hydrolytically stable cross-linked 
poly(2-hydroxyethyl methacrylate) (HEMA). The permeability and hydrophilicity of 
these gels are dependent on the cross-linking agents.[160] Poly(HEMA) has been 
used for ophthalmic uses including contact lens,[161] as well as in many drug 
delivery applications.[162] Macroporous poly(HEMA) gels have been prepared by 
freeze/thaw, or particulate leaching techniques for cartilage replacement.[163] Many 
different types of molecules and cells have also been encapsulated into poly(HEMA) 
gels, and this approach has been reported to be successful for delivery of insulin or 
other proteins into the body.[165] Poly(HEMA) gels are not degradable in 
physiological conditions. Therefore, dextran-modified poly (HEMA) gels have been 
synthesized, and reported to be degradable by enzymes.[166] In addition, 
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enantiomeric oligo(L-lactide) and oligo(D-lactide) were grafted to poly(HEMA) to 
induce stereocomplexation, resulting in the formation of poly(HEMA) gels without 
using any toxic chemical reagents.[166] 
Poly(N-isopropylacrylamide) (PNIPAAm) is potentially very attractive for tissue 
engineering applications as it exhibits phase transition behavior above the lower 
critical solution temperature (LCST). The LCST of PNIPAAm in water is 
approximately 32 C and can be matched to body temperature by 
copolymerization.[167] Therefore, the use of PNIPAAm and its copolymers in tissue 
engineering would be very beneficial as one can easily prepare a mixed solution of 
cells and the polymer at room temperature or even at a lower temperature and inject it 
into the desired site. This will result in the formation of a solid cell/polymer construct 
as the gel warms to body temperature. NIPAAm has been copolymerized with acrylic 
acid, methacrylic acid, or butylmethacrylic acid, depending on the desired final 
applications.[168, 169] Acrylamide derivatives have also been cross-linked with 
native proteins,[170] oligodeoxyribonucleotides, [171] or engineered coiled-coil 
proteins [172] to form temperature-responsive gels. In this situation, conventional 
polymers could potentially be modified to exhibit thermal transition behavior by 
utilizing a variety of cross-linking molecules that can induce phase separation in 
response to temperature changes.  
The unique temperature-responsive nature of these polymers is leading to a variety of 
biological applications. In standard cell culture, cells are recovered from the dishes by 
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treatment with proteases (e.g., trypsin). However, the culture of cells on PNIPAAm 
enables one to easily recover intact cell sheets without damage by simply decreasing 
the temperature and modulating the hydrophilicity of the gel. [172] These polymers 
are also being investigated as an injectable delivery vehicle for cartilage and pancreas 
engineering [168]. This mechanism of phase transition may be ideal for delivery of 
cells, as unlike chemically controlled cross-linking (e.g., alginate), the timing of phase 
transition is not set, but simply depends on the temperature change upon introduction 
to the body. However, limitations of these gels are the nondegradable cross-links, and 
the vinyl monomers and cross-linking molecules are toxic, carcinogenic, or 
teratogenic. In an effort to obviate these issues, dextran-grafted PNIPAAm 
copolymers have been synthesized, and these may modulate degradation in 
synchronization with temperature.[173]  
4.2.2 PEO and its copolymers 
Poly(ethylene oxide) (PEO) has been approved by the FDA for several medical 
applications due to its biocompatibility and low toxicity. It has been extensively 
studied for uses including preparation of biologically relevant conjugates, [174] 
surface modification of biomaterials, and induction of cell membrane fusion. [175] 
PEO itself is very hydrophilic and can be synthesized by anionic or cationic 
polymerization of ethylene oxide. PEO gels can be prepared by UV 
photopolymerization of the precursor that consists of PEO with acrylate termini at 
each end in the presence of -hydroxy acid. [176] The peptide sequence of Ala-Pro-
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Gly-Leu has also been introduced into these gels, to make the gels susceptible to 
enzymes existing in the body, and these gels may be useful for tissue engineering 
applications. [177] Branched PEO having a cinnamylidene acetyl moiety as a pendant 
group has been synthesized and photopolymerized to form gels, and these gels 
demonstrated antithrombogenic properties. [178] Star-shaped PEO was cross-linked 
by irradiation to form hydrogels and also modified with galactose moieties to enhance 
the interaction with liver cells. [179]  
Various PEO-based copolymers have been reported and utilized, especially in drug 
delivery applications. [180] One interesting copolymer is a triblock copolymer of 
PEO and poly(propylene oxide) (PEO-b-PPO-b-PEO), which is known by the trade 
name Pluronics or Poloxamers, and is commercially available in various lengths and 
compositions. These polymers form thermally reversible gels without any permanent 
cross-links, unlike PNIPAAm and its copolymer gels. In addition, it was reported that 
PEO-PPO-PEO triblock copolymers could be designed to form gels at body 
temperature by forming a liquid crystalline phase. [181] PEO-PPO triblock 
copolymers have been mainly used for drug delivery applications, as they are known 
to enhance drug penetration, and also enhance the activity of antineoplastic agents 
against tumors. [182] There have been few reports on the utilization of these gels in 
tissue engineering to date,[183] but they may find multiple applications in this field.  
The synthetic polymers have good mechanical characters, while the natural polymers 
have better biocompatible. So in our study, the synthetic polymer (PHEMA) was 
 42
prepared as support scaffold and collagen was used as the ECM scaffold for cell 
container. 
4.3 In situ gelling hydrogel scaffolds 
In the past few years, an increasing number of in situ-forming systems have been 
reported in the literature for various biomedical applications, including drug delivery, 
cell encapsulation, and tissue repair. These systems are injectable fluids that can be 
introduced into the body in a minimally invasive manner prior to solidifying or 
gelling within the desired tissue, organ, or body cavity. Injectable gel-forming 
matrices offer several advantages over systems shaped into their final form before 
implantation. For example, injectable materials do not require a surgical procedure for 
placement (and withdrawal if not biodegradable), and various therapeutic agents can 
be incorporated by simple mixing. When they are used to fill a cavity or a defect, their 
flowing nature enables a good fit. In situ implant formation can occur as a result of 
either a physical or chemical change of the system.  
 
There are several possible mechanisms leading to in situ implant formation. The 
solvent exchange approach consists of dissolving a water-insoluble polymer in a 
water-miscible, biocompatible solvent. Upon contact with body fluids, the solvent 
diffuses out of the polymer while water permeates the liquid polymer matrix. Due to 
its insolubility in water, the polymer precipitates, resulting in the formation of a solid 
polymeric implant [184]. However, incomplete implant formation can be observed in 
vivo resulting in a high initial release and local or systemic toxicity. Also, the organic 
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solvent was used to solubilize the polymer can physically denatured labile compounds 
such as proteins. Photo polymerization has also been proposed to prepare in situ 
implants. This approach has been taken to produce depot formulations [185], 
biological adhesives for soft tissues [186], and orthopaedic biomaterials [187]. 
However, photopolymerization requires the presence of a photoinitiator at the gelation 
site, which can be toxic. Furthermore, the penetration capacity of the radiation source 
limits the number of application sites, and the reaction can evoke enough heat to 
damage surrounding tissues.  
 
In situ-forming systems that do not require organic solvents or copolymerization 
agents have gained increasing attention. These are liquid aqueous solutions before 
administration, but gel under physiological conditions. Gelation can occur in situ by 
ionic cross-linking [188] or after a change in pH [189] or temperature. The latter 
approach exploits temperature-induced phase transition.  
 
The ideal system would be a solution that is a free-flowing, injectable liquid at 
ambient temperature. It should then gel at body temperature with minimal syneresis. 
Moreover, loading with drugs or cells should be achieved by simple mixing. When 
administered parenterally, these systems should exhibit a pH close to neutrality and 
should be bioresorbable. This paper focuses on polymeric solutions that can form 
implants in situ in response to temperature change, from ambient to body temperature. 
It mainly reviews the characterization and use of polysaccharides, N-
 44
isopropylacrylamide (NIPAM) copolymers, poly(ethylene oxide-b-propylene oxide-b-
ethylene oxide) (PEO-PPO-PEO) and its copolymers, poly(ethylene oxide)/(,-lactic 
acid-co-glycolic acid) (PEO/PLGA) copolymers, and thermosensitive liposome-based 
systems.  
 
4.4 Hydrogels with phenylboronic acid moieties 
All of the preceding studies utilized proteins, such as glucose oxidase or lectins, for 
the fabrication of glucose-sensitive hydrogels. This section focuses on the preparation 
of glucose-sensitive hydrogels without biological components such as proteins, but 
instead complex formation between a phenylboronic acid group and glucose.  
Phenylboronic acid and its derivatives form complexes with polyol compounds, such 
as glucose in aqueous solution. The complex between phenylboronic acid and a 
polyol compound can be dissociated in the presence of a competing polyol compound 
which is able to form a stronger complex. This means that complex formation 
between phenylboronic acid and a polyol compound has many potential applications 
as a glucose-sensitive material.  
Kitano et al. [213 and 214] synthesized copolymers with phenylboronic acid moieties 
(poly(NVP-co-PBA)) by copolymerizing N-vinyl-2-pyrrolidone (NVP) and 3-
(acrylamido)phenylboronic acid (PBA). (figure 2) Due to the reversible complex 
formation between phenylboronic acid of poly(NVP-co-PBA) and poly(vinyl alcohol) 
 45
(PVA), the competitive binding of phenylboronic acid with glucose and PVA could 
be utilized to construct a glucose-sensitive system. The formation and dissociation of 
the poly(NVP-co-PBA)/PVA complex could be investigated by observing the change 
in viscosity. Viscosity measurements revealed that poly(NVP-co-PBA) formed a 
complex with PVA in the absence of glucose, however the complex dissociated in the 
presence of glucose. These results led to the concept of a glucose-sensitive insulin 
release system using poly(NVP-co-PBA) and PVA [214]. An electrode coated with 
the poly(NVP-co-PBA)/PVA complex is an example of the potential of this system 
for the development of glucose-sensitive devices [215]. The presence of free glucose 
resulted in swelling of the poly(NVP-co-PBA)/PVA complex hydrogel, due to 
complex dissociation. Thus, the electrode coated with poly(NVP-co-PBA)/PVA 
complex hydrogel could be utilized as a glucose sensor, as the current changes were 




Scheme.2 . Concept of a glucose-sensitive insulin release system using 
PVA/poly(NVP-co-PBA) (polymer capsule type).  
It is difficult to use the poly(NVP-co-PBA)/PVA complex as a glucose-sensitive 
insulin release system, because of its intrinsic instability at a physiological pH of 7.4. 
To stabilize complex formation between phenylboronic acid and glucose at a 
physiological pH of 7.4, amino groups were introduced either into the polymer or in 
the vicinity of the phenylboronic acid moiety [216]. Furthermore, a glucose-sensitive 
hydrogel possessing both phenylboronic acid and amino groups was prepared for the 
development of a novel glucose-sensitive insulin delivery system at physiological pH 
[209]. This glucose-sensitive insulin delivery system was based upon the complex 
formation between gluconated insulin and the phenylboronic acid groups in the 
hydrogel. The gluconated insulin was released from the hydrogel in the presence of 
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free glucose, which induced the dissociation of the complex. This system was able to 
achieve an insulin release in response to the glucose concentration at a physiological 
pH. PBA exists in equilibrium between the uncharged and the charged form. Complex 
formation between the uncharged form and glucose was shown to be unstable because 
of its high susceptibility to hydrolysis, while charged phenylboronic acid groups were 
able to form a stable complex with glucose. Complex formation between the charged 
phenylboronic acid groups and glucose caused a shift in the equilibrium towards an 
increase of charged phenylboronic acid groups. Therefore, the total amount of 
charged phenylboronic acid groups increased and uncharged groups decreased when 
glucose was added. A change in the ratio of the uncharged to charged forms by the 
addition of glucose influenced the solubility of the polymer in water. The change in 
solubility indicated that the shift in the equilibrium between the uncharged and 
charged forms of the phenylboronic acid groups can be used to develop glucose-
sensitive systems. Kataoka et al. [213] prepared a copolymer of N,N-
dimethylacrylamide and PBA, which had a low critical solution temperature (LCST) 
of about 27°C, in a buffer solution of pH 7.4. The fact that a copolymer without the 
phenylboronic acid groups had no LCST suggested that the phenylboronic acid 
groups played an important role in the appearance of LCST. LCST of the copolymer 
with the phenylboronic acid groups increased continually with the addition of glucose. 
This change in the glucose-sensitive LCST was attributed to an increase in 
hydrophilic, charged phenylboronic acid groups caused by complex formation 
between the phenylboronic acid groups and glucose.  
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Basing on the principles of in situ gelation hydrogel and Hydrogels with 
phenylboronic acid, we prepared a novel in situ gelation collagen scaffold for the 
hepatocyte culture in vitro. The scaffold has good biocompatible and mass transfer 
character.  
5. Liver tissue engineering  
Finally, different biomaterials and engineered devices are for an artificial liver to 
replace the deficit functional liver, which suffered from disease.  The aim of our 
project is for designing a suitable device for the liver tissue engineering. 
5.1 The role of liver tissue engineering 
The liver plays a central role in a broad spectrum of physiological functions[217], and 
represents a significant tissue engineering challenge. Liver functions include 
metabolism, storage, synthesis and release of vitamins, carbohydrates, proteins, lipids 
and cyclic tetrapyrroles. The liver detoxifies and inactivates endogenous and 
exogenous substances, including toxins and metals, and activates precursor molecules, 
such as proenzymes and coagulation factors. The liver also produces bile, which is 
involved in intestinal lipid absorption, and secretes a majority of circulating plasma 
proteins. Liver tissue engineering research has focussed on transplanting hepatocytes, 
the liver parenchymal cells that perform most liver functions and make up 80% of 
liver cytoplasmic mass.[218] 
Strategies used to develop implantable systems that provide long-term hepatic support 
are reviewed here. Implantable systems could provide permanent hepatic support, 
provided they are properly integrated into the body. We place particular emphasis on 
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biodegradable scaffolds that permit tissue remodelling and eventually resorb, thereby 
eliminating chronic foreign body responses. Extracorporeal hepatic support systems 
are alternatives to implantable devices, and have been reviewed recently. [219, 220, 
221, 222, 223, 224] 
 
5.2 Direct injection, microcarrier and encapsulation system  
Liver tissue engineering research began more than 20 years ago when investigators 
dissatisfied with hazards, difficulties and inconsistencies associated with hepatic 
support systems transplanted hepatocytes as free grafts by direct injection into various 
organs, body cavities, or blood vessels[222, 223]. Direct injection studies used the 
recipients’ stromal tissue to provide extracellular matrix (ECM) required for 
hepatocyte growth and differentiation [224, 225]. Corrections of metabolic defects 
and chemically induced liver failure for periods ranging from 2 weeks to over 1 year 
were reported [226, 227, and 228]. However, significant necrosis and granuloma 
formation in transplanted hepatocytes were also observed”. Hepatocyte aggregates 
transplanted intrasplenically exhibited improved long-term survival and differentiated 
hepatic function out to 2 years relative to individual hepatocytes, although the 
proliferative capacity of transplanted aggregates appeared limited.  
Transplantation of hepatocytes encapsulated hepatocytes over 5 weeks demonstrated 
continued, although decreasing, production of proteins and metabolites. [229]  In vivo, 
encapsulated hepatocytes decreased serum bilirubin levels in Gunn rats for up to 4 
weeks and increased, by almost 80%, survival times of rats subjected to 
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galactosamine-induced fulminant hepatic failure (FHF) (ref). As with islet 
encapsulation, protection of transplanted hepatocytes from immune surveillance is an 
important advantage of these systems.[229] At present, encapsulation strategies and 
microcarrier systems may be most effective at providing temporary hepatic support, 



















Chapter2   Synthesis and characterization of materials in 3-
D cell culture systems 
 
 
The primary function of extra-cellular matrix is to endow tissues with their specific 
mechanical and biochemical properties.  The most abundant family is the collagens 
with more than 20 different collagen types identified so far. Type I collagen is the 
most abundant and best-studied collagen. [17,18] 
 
Many studies showed that the hepatocytes could attach in the collagen scaffold and 
hydrogel. [71] On the other hand some studies also identified some sequences of 
peptide in the collagen are involved in the cell proliferation and differentiation 
pathway. [72] Scaffolds coated by collagen and collagen three dimensional scaffolds 
were used as ECM in liver tissue engineering. Hydrogels were also wildly used in 
liver tissue engineering, because of the characters of hydrogel, such as the highly 
water absorption, materials surface and mechanical characters. 
 
The galactosylated biomaterials have been prepared for the liver tissue engineering. 
The galactosylated chitosan [94], galactosylated alginate [95] have been applied in 
hepatocyte culture in vitro as the ECM of hepatocytes. The galactosylated 




In our previous works, the methylated collagen has been used to form microcapsules 
with polymer (PHEMA-MMA-MAA). Hepatocytes show better functions than 
monolayer culture [134]. The mechanical strength of microcapsules and effects of 
molecular weight of polymer have also been studied.  
 
In this study, basing on the interaction between ASGPR and galactose group, the 
galactose group was conjugated to amino or carboxyl group on collagen respectively 
to enhance cell functions of hepatocytes in microcapsules and scaffolds.  
 
We also prepared a kind of in situ forming galactosylated collagen which was gelled 
in porous PHEMA hydrogel. In this system, galactosylated collagen reacts with APBS 
to form the in situ gelling scaffold. The porous PHEMA scaffold supports the in situ 
gelling galactosylated collagen, which entraps hepatocytes. On the other hand, culture 
media is easy to penetrate into the PHEMA scaffold.  
 
The galactosylated collagen also been used to form microcapsules to enhance cell 
functions of hepatocytes. The microcapsules were formed by the coacervation of 
galactosylated collagen and ter-polymer. On the other hand, galactosylated collagen 
was provided as a suitable ECM for hepatocytes. 
 
 
1 Material and method 
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1.1 materials 
Lactobionic acid(Aldrich), MES buffer(Sigma), mercaptanol(Sigma), Sulfo-
NHS(Sigma), EDAC (Sigma), NHS(Sigma), ethylenediamine (Sigma), 1, 4-
aminophemylboronic acid (Sigma), 1.3-propanol (Fluka), succinic acid (Sigma), DCC 
(Sigma),  pyridine (Sigma), HEMA(Sigma), NaCl(Sigma), AIBN(Sigma), 
collagen(Sigma),  
 
1.2 Collagen methylation 
       Type I Bovine dermal collagen (Vitrogen) was modified to be cationic via 
esterification as described previously [134]. The degree of methylation was controlled 
by adjusting the time and temperature of the reaction and characterized by a capillary 
electrophoresis method [230]. Briefly, the methylation reaction involved stirring the 
precipitated collagen in acidified methanol for 4°C, followed by dialysis to pH 7.4, 
freeze-drying. The characterization of the degree of methylation involved separations 
on a CE-L1 System (CE Resources Pte Ltd) with 0.05% hydroxypropyl methyl 
cellulose at pH=2.5 and 21°C, which resolved the methylated collagen into four major 
peaks. An increase in the degree of methylation was correlated to an increase in the 
ratio of the areas under the last two peaks over the first two, defined as γ [230]. 
Collagen methylated at 4oC, 6 days had a lower γ of 1.4. 
 
1.3 Synthesis and characterization of N-galactoylated collagen 
The galactosylated collagen was prepared as the modified commercial protocol. 
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[232]The LA (1mmol) dissolved in 10ml MES buffer (pH=4.5) was mixed with 
EDC(10mmol) and sulf-NHS(1.1mmol) MES buffer solution(pH=4.5, 10ml) and was 
reacted for 15 minutes. The mercaptanol was added to the reaction solution to stop the 
activity reaction after 15 minutes. The reactivated LA was added to the collagen 
solution (0.3mg/ml, 100ml) with fast stirring. The mixed collagen solution reacted at 
4 °C for about 24 hours. Then, the collagen solution was dialysis in DI water for 3 
days in 5000ml bottle; the water was changed twice everyday. The solution was 
freezing-dried for 3 days. The reaction showed as scheme 3.  
 
1.4 The synthesis and characterization of Galactosylated collagen (conjugated on 
the carboxyl group) (G-C-collagen). 
1.4.1Preparation of N-lactobionic acryl etheylenediamine 
The synthesis of N-lactobionic acryl etheylenediamine was modified from the 
reference. [231] Lactobionic acid (358mg, 1mmol), EDAC (394mg, 2mmol) and NHS 
(126mg, 101mmol) was dissolved in the methanol and then refluxed at 60 ℃ for 1 
hour to afford the activated carboxyl group in LA. Then the mixture was dropped into 
the ethylenediamine (600ul, 10mmol) slowly. The N-lactobionic acryl 
ethylenediamine was prepared. The compound was Purified gel-filtration 
chromatography. The product was identified by HNMR. 
 
 1.4.2 Preparation of C-galactosylated collagen 
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The galactosylated collagen was prepared as the described previously. [232] Collagen 
(3mg/ml, 10ml) was dissolved in MES, NaCl, and buffer(pH=4.5) to the final 
concentration of 0.3mg/ml. EDC (114.6mg,0.6mmol) and sulfo-NHS 
(12.96mg,0.06mmol) was added to collagen-MES buffer to obtain the final 
concentration of 2mM EDC and 0.2mM sulfo-NHS. The mixture was reacted for 
15min at room temperature. Add 2-mercaptoethanol to the reaction solution to obtain 
a final of 2mM. The N-lactobionic acryl ethylenediamine was added to the 







































































































modification degree, the reaction time from 2 hours to 24 hours), then the excess 
reactants were removed by dialysis. The reaction showed as scheme 3 
1.4.3 Characterization of modification degree of galactosylated collagen 
The degree of collagen galactosylation was quantified by a modified colorimetric 
assay [233]. Briefly, 15ml galactosylated collagen (3mg/ml) was mixed with 95ml 
concentrated sulphuric acid and 15ml phenol and incubated at 30℃ for 1h. The 4 
coloration degree was measured by a colorimeter (wavelength=510 nm) using 
different concentrations of D-galactose PBS solutions as standards and modified 
collagen (3mg/ml) as negative control. The degree of galactosylation, which is the 
percentage of carboxyl groups in collagen modified with galactose, was difference by 
the reaction time and reaction temperature.  
 
1.5 Preparation of 1,4-Aminophenylboronic acid-succinic acryl(APBS) 
The 1,4-Aminophenylboronic acid-succinic acryl(APBS) was prepared as the 
described.[234] The 1, 4-aminophenylboronic acid (1mmol) dissolved in pyridine was 
mixed with 1.3-propanol (1.2 mmol) and reacted at 60 °C for about 2 hours. The 
mixture was dropped into the succinic acid (0.9mmol) and DCC (3mmol) pyridine 
(10ml) solution in 30 minutes. The solution  wasreacted for about 12 hours. After the 
reaction, the solution was filtrated and the filtrated solution was concentrated. The 
concentrated solution was dropped into ice-water and yellowish powder was 
precipitated, then the precipitation was re-crystalled by water. The final product is 
































1.6  Preparation of PHEMA hydrogel 
The monomer HEMA (200ul) and the different amount of PEG-diacrylate were mixed 
with different particle size sodium chloride (200mg) in 2 ml plastic tube. The air in 
the tube was expelled by the Argon. The initiator, AIBN (Final concentration=1mg/ml, 
5ul) dissolved in iso-propanol was injected into the plastic tube. The mixture was set 
in the vortexor with hot plate. The monomer polymerized at 60 °C for 24 hours under 
the air of Argon.  
The PHEMA was prepared under different reaction conditions and different reactant 
ratio. Table1 shows the different PHEMA hydrogel scaffold. 
 
1.7 Image the structure of PHEMA  
The PHEMA was immersed in the pure water and kept in water for 24 hours, after 
which the PHEMA was frenzied in -80 °C and freezing-dried for 3 days. The dried 
slips was coated by gold and detected by SEM. 
 
1.8 Characterization of swelling ratio of PHEMA hydrogel in hepatozyem. 
Water absorption is one of the most important characters for the hydrogel. The dried 
PHEMA slips were weighted first, the dried PHEMA slips were put into the 
hepatozyme and weight the every slip at different time points; 5 minutes, 15minutes, 
30 minutes, 60 minutes, and 120minutes. The additional weight was divided by the 























Table 1 Different PHEMA prepared under different reaction conditions 
 
 1 2 3 4 5 6 7 8 9 
HEMA(ul) 200 
PEG-diacrylate(ul) 10 5 1 10 5 1 10 5 1 





 1 2 3 4 5 6 7 8 9 
HEMA(ul) 200 
PEG-diacrylate(ul) 10 5 1 10 5 1 10 5 1 
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1.9 Permeability of porous PHEMA hydrogel 
The scaffolds was immersed in 2ml FITC-Dextran (10mg/ml; Mw=70,000) for about 
24 hours to balance the concentration between inside and outside of hydrogel. Then 
the scaffolds loaded by FITC-dextran were washed three times and immersed into the 
5ml hepatozyme. 50ul solution outside scaffolds was collected at different time points 
(every 5 minutes).  
 
2 Results 
2.1 Modification degree of N-galactosylated collagen at different modification 
reaction conditions 
From graph 1, the modification degree of galactosylated collagen, which reacted at 4 
°C, is about 16% after 2 hours; while the modification degree of galactosylated 
collagen, which reacted at 20°C, is about 18% after 2 hours. Modification degrees of 
galactosylated collagen, which was reacted at 4°C, are about 34% and 51% after 8 
and 12 hours, respectively.  At the same reaction time, the modification degrees of 
galactosylated collagen, which was reacted at 20°C, are as high as 50% and 78% 
respectively. When the reaction time is more than 24 hours, the modification degree of 
galactosylated collagen, which was reacted at 4 °C, is about 84%, while the 
modification degree of galactosylated collagen, which was reacted at 20 °C, is about 
89%.  
 




The graph 2 showed that the modification degree was about 16% at 2hours, which 
reacted both at 4 °C and 22 °C. When the reaction time was about at twelve hours, the 
modification degree increased to 38% at 4°C, while the modification degree increased 
to about 60% at 22 °C . When the reaction time is 24 hours, the modification degree 
of galactosylated collagen, which was reacted at 4 °C, increased to 83%, while the 
modification degree of galactosylated collagen, which reacted at 22 ℃, was also 
about 83%. When the reaction time is 48 hours, the modification degree of G-collagen 
at 4°C and 22°C were 92% and 91%, respectively.  
 
 
2.3 Image of  porous PHEMA hydrogel structure 
 
The pore size of PHEMA hydrogel mixed with the NaCl (particle size=100µm) was 
about 100±10µm. While the pore size of PHEMA hydrogel mixed with NaCl (particle 
size=200µm) was about 200±23µm. By other words, the pore size was not significant 
difference between the sample 4 and sample 6 which were reacted under different 




































Graph 1 Modification degree of N-galactosylated collagen at different reaction 



















































































Scaffold reacted with the NaCl (particle size= 200um) 
   





Scaffold reacted with the NaCl(particle size= 100um) 
   
                       4(100)                                                                   6(100) 
Figure 1 Porous PHEMA hydrogenl, whose pore was formed by NaCl particles (particle 





















































Graph3 Swelling ratio of PHEMA prepared by different amount of PEG-diacrylated and 
initiator, while the same particle size of NaCl (100µm). The sample1-9 was showed 






































Graph4 Swelling ratio of PHEMA prepared by different particle size NaCl. The sample 2, 
5, and 8 are as table 1 
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2.4 Swelling ratio of different PHEMA hydrogel scaffolds 
 
Form graph 3 and the graph 4, the swelling ratio of scaffold increased with the 
increasing of amount of initiator, AIBN, when the same amount of PEG-diacrylate 
was added. As the 10ul of PEG-diacrylate was added, PHEMAs absorbed about 35% 
and 100% water at the 5mins and 240mins respectively, when 0.2ug initiator was 
added. PHEMAs absorbed about 20% and 82% water at 5 minutes and 240 minutes 
respectively while 0.05ug initiator was added. When the 5ul PEG-diacrylated was 
added, scaffolds had the highest swelling ratio while the same amount of initiator was 
added. When 0.2ug AIBN was added in the reaction system, swelling ratios of 
PHEMA, which was polymerized with 5ul PEG-diacrylated, were about 69% and 
161% at 5 minutes and 240 minutes respectively. When PHEMAs were polymerized 
with 10ul and 1ul PEG-diacrylated, swelling ratios were about 109% and 132% 
respectively. Under the same reaction conditions and same reactants ratios, Swelling 
ratios of scaffolds formed with the NaCl (Particle size=100um) were higher than those 
formed with the NaCl (particle size=200)  
 
2.5 permeability of porous PHEMA hydrogel 
The different PHEMA hydrogel scaffolds were prepared by different particle sizes of 
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From the graph 5, FITC-dextran, which was released from hydrogel scaffolds, was 
very quick in the beginning 15 minutes. Sample 4 released 6 mg FITC-dextran at 15 
minutes, while it released 8.2 mg FITC-dextran at 120 minutes. Sample 1 released 
about 4.2 mg FITC-dextran at 15 minutes, while it released about 7 mg FITC-dextran 
at 120 minutes. At 30 minutes, the amount of FITC-dextran released form sample1 
and sample 2 were not significant different. The difference of sample 3 and sample 4 
was also not significant at 15minutes. More FITC-dextran was released from sample 3 
and sample 4 than that was released from sample1 and sample 2, respectively. There 
was about 6.3 mg FITC-dextran, which was released from sample 4 at 15 minutes, 
while there was only about 4.2 mg FITC-dextran, which was released from sample 2 
at the same time. There were 5.0 mg FITC-dextran, which was released from sample 
3 at 15 minutes, while there were about 4.2 mg FITC-dextran, which were released 
from sample 1. At 120 minutes, the amount of FITC-dextran released from scaffold 




              3.1 Modification degree of galactosylated collagens 
Form graph 1 and graph 2, modification degrees of galactosylated collagen only 
depended on the reaction time and reaction temperature. The higher reaction 
temperature, the higher modification degrees of galactosylated collagen are. When the 
temperature increases 1 degree, the reaction velocity will increase 10 times. So At the 
same time point, the modification degrees of galactosylated collagen at 20 C is higher 
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that those at 4 C. but The highest modification degree may depend on the 
concentration of lactobionic acid and number of activated group on collagen . In other 
words, when the reaction time was more than 24 hours, the modification degrees were 
not significant different between different collagen which was galactosylated at 
different temperature. It imply that the highest modification degree is only determined 
by the reaction type and the concentration of reactant. The reaction under higher 
temperature also caused the crosslink of collagen in solution. The possible reason is 
that at higher temperature, the collagen molecules move quickly in the solution. So 
the amino group and carboxyl group on the collagen chain will react easily at high 
temperature. Therefore, the lower reaction temperature and the lower concentration of 
collagen will decrease the chance of crosslink between different collagen chains. On 
the other hand, the higher concentration of Lactobionic acid will increase the reaction 
chance between Lactobionic group and collagen. So low temperature, low 
concentration of collagen and high concentration of lactobionic acid are optimized 
reaction conditions for highly modification degree of galactosylated collagen. .  
 
3.2 Swelling ratio of PHEMA hydrogel formed under different reaction 
conditions.  
From graph 3 and graph 4, swelling ratios of hydrogel increased with the decreasing 
of the amount of initiator when the same PEG-diacrylated was added. It implies that 
the increase of crosslinking degree and molecular weight of PHEMA decrease the 
permeability of porous hydrogel. With the increasing of AIBN, the crosslink degree 
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by PEG-diacrylated and molecular weight decrease. The high crosslink degree of 
PHEMA network will restrict molecules of water to penetrate into the PHEMA 
scaffold. On the other hand, the higher molecule weight increases the hydrophobiaty 
of PHEMA scaffold, whose hydrophobic force will keep molecules of water out of 
HPEMA scaffold. 
When the same AIBN, initiator of polymerization, was added, swelling ratios of 
hydrogel were the highest as 5 ul PEG-diacrylated was added in the monomer 
solution. The reasons may be that the PEG chain is hydrophilic. When the PEG-
diacrylated increased from 1ul to 5 ul, the HPEMA scaffolds are more hydrophilic. So 
molecules of water easily enter PHEMA scaffolds. However, PEG-diacrylated is also 
a crosslink reagent. When more PEG-diacrylated was added in the monomer, the 
crosslink degree increases. The higher density of PHEMA network will limit the entry 
of water molecules. So when the amount of PEG-diacrylated increased from 5ul to 
10ul, the swelling ratio decreased.  
The different particle sizes of NaCl were also used to form different pore sizes in 
PHEMA scaffolds. Swelling ratios of PHEMA with 100um pore size are lower than 
those of PHEMA with 200um pore size before 60 minutes. However, after 60 minutes, 
swelling ratios of PHEMA with 100um pore size are similar with those of PHEMA 
with 200um pore size. It implies that more water will be kept in bigger pores, but the 
molecule weight and crosslink density influence the total amount of water which is 
absorbed by HPEMA scaffolds. When scaffolds are immersed in water, the solution 
will be absorbed into the pore in the porous PHEMA, and then the water will be 
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absorbed into the PHEMA hydrogel. The bigger pores can contain more water in short 
time, so more water is absorbed into the porous scaffolds in short time, after which 
the amount of water absorbed by the HPEMA hydrogel only determined by the 
molecule structure of PHEMA hydrogel.  
  
3.3 Pore size of PHEMA by different pore size maker, different amount of 
initiator and different amount of PEG-diacrylated. 
The SEM picture showed that the pore size was only determined by particle sizes of 
NaCl. It implies that NaCl particles are inertia during the polymerization reaction and 
cannot be dissolved in the solution. The scaffold is formed surround the NaCl 
particles. After NaCl particles are washed out, pore sizes of different molecular 
structure are similar, when the same particle size NaCl is mixed with the reactants. 
3.4 Relationship between structure of PHEMA hydrogel and the character of 
permeability.  
FITC-dextran was released quicker from the hydrogel formed with the NaCl (particle 
sizes=200um) than that released from PHEMA formed with NaCl (particle 
size=100um) in the first 30 minutes. But there are no significant differences between 
two HPEMA scaffolds after immersed in the media after 30 minutes. That may be that 
FITC-dextran stored in pores of porous PHEMAs is released out quickly in short time 
and then FITC-dextran stored in the HPEMA hydrogels is released slowly. On the 
other hand, the release of FITC-dextran stored in HPEMA hydrogel is only 
determined by the molecular structure of PHEMA Porous PHEMA whose pore size is 
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200um can store more FITC-dextran solution and release more in short time. 
Otherwise, the release of FITC-dextran in PHEMA hydrogel was only determined by 
chemical structure of PHEMA, except the pore sizes of porous PHEMAs. 
The release of FITC-dextran from PHEMA, which was initiated by 1 ug AIBN, was 
slower than that from PHEMA, which was initiated by 10 ug AIBN. It also implies 
the chemical structure determines the release of FITC-dextran expect the pore sizes of 
porous PHEMAs. With the increasing of AIBN in reactants, the molecule weight and 
crosslink degree decrease. Otherwise, FITC-dextran is easier to release from PHEMA 
hydrogel, which molecule weight and crosslink degree is lower.  
4. Conclusion 
In this section, the materials in the research about galactosylated collagen and 3-D 
culture environment have been synthesized and characterized. The galactosylated 
collagen was synthesized under different reaction conditions. The degree of 
galactosylation was adjusted by the reaction temperature and reaction time. We also 
found that collagen is easy to crosslink and precipitate when reaction temperature is at 
20 ºC. Above all, reaction conditions have been optimized.  
Porous PHEMAs have been prepared and the characters of porous PHEMA have also 
been tested. Porous PHEMAs are a hydrophilic scaffold, which have the suitable 
permeability. Characters of PHEMA scaffold can be optimized by the amount of 




Chapter 3 Characters of microcapsules formed by the galactosylated 
collagen and poly (HEMA-MMA-MAA) 
 
In vivo, hepatocytes are supported in specific architectures imposed by extra-cellular 
matrices (ECM) comprising a 3-D environment with other collagen and many types 
of glyco-proteins. These ECMs play a crucial role for cell-viability and also sever 
an important function as a scaffold. In previous studies, the alginate has been used 
to entrap hepatocytes. The ammonia metabolism and cell survival have also been 
tested. [92]  
In previous works, methylated collagen has been used to form microcapsules with 
poly (HEMA-MMA-MAA). Hepatocytes showed much better functions than those 
cultured as monolayer. Relationships between mechanical strength of microcapsules 
and molecular weight of polymer have also been studied.[134] In this study, Basing 
on the interaction between surface receptor of hepatocytes (ASGPR) and galactose 
group,[87] the galactose group was conjugated to the carboxyl group on collagen to 
enhance the attachment and cell functions of hepatocytes in microcapsules. The 
permeability of microcapsules has been tested. The pore size of microcapsules 
surface has also been tested by the SEM. The distribution of Galactosylated 
collagen and methylated collagen has been imaged by Laser Confocal Microscopy. 
Our previous work showed that the mechanic support is an important factor about 
the hepatocytes functions. [235] We have also quantities the density of nano-fiber 
network in microcapsules. [235] 
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1 materials and methods  
1.1 materials 
C-galactosylated collagen, Poly (HEMA-MMA-MAA), glutaraldehyde (Sigma), 
FITC (Sigma), Rhodamine (Sigma), Methylated collagen, FITC-dextran (sigma; 
Mw=70,000) 
 
1.2 preparation of microcapsules formed by the poly (HEMA-MMA-MAA) and 
the mixture of galactosylated collagen and methylated collagen 
The hepatocytes were mixed with modified collagen, after which the mixtures were 
dropped to the polymer solution to form microcapsules. Then microcapsules were 
washed by the culture media three times. Finally microcapsules were cultured in the 
hepatozyme. In this study, methylated collagen and galactosylated collagen were used 
to form the core of microcapsules. The different modification degree galactosylated 
collagen was used to evaluate the effect of galactose groups to cell functions of 
hepatocytes in microcapsules. Microcapsules, which were made from different mix 
ratios of methylated and galactosylated collagen, were also prepared to optimize cell 
functions of hepatocytes in different microcapsules. Different microcapsules were 
prepared as the table 3 and table 4 showed. 
 
1.3 The permeability of collagen microcapsules 
 In this experiment, FITC-dextran (MW=7X105) was used to evaluate the 
permeability of different microcapsules. Briefly, microcapsules were made from 500 
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ul mixed collagen and the 500ul FITC-dextran solution (10mg/ml). The concentration 
of FITC –dextran out of microcapsules was calculated to evaluate the permeability of 
microcapsules.  
 
1.4 Surface of microcapsules by SEM 
Microcapsules are cultured in hepatozyme for 24 hours. The hepatozyme was 
removed and the microcapsules were fixed with 3% glutaraldehyde on a coverslip 
coated by poly-L-lysine for 2 h, after which they were washed gently with PBS for 5 
min. The microcapsules were then post-fixed with osmium tetra-oxide for 1 h and the 
microcapsules were washed by PBS 3 times. The microcapsules were then put into the 
liquid nitrogen form about 15 minutes, after which the microcapsules were dried by 
freezing-dryer under 89X10-3 Pa. the microcapsules mounted onto an aluminum stub 
and sputter coated with gold before viewing under a scanning electron microscope 























Table 3 Microcapsules prepared by the different modification degree galactosylated collagen 
 
  Methylated collagen (M-
collagen) 
Galactosylated collagen 
(modification degrees of G-
collagen) 
1A 50ul 150ul (83%) 
1b 30ul 150ul (83%) 
2A 50ul 150ul (37%) 
2B 30ul 150ul (37%) 
3A 50ul 150ul (16%) 
3B 30ul 150ul (16%) 




Table 4 Microcapsules prepared by different mixed ratios of methylated collagen and 
Galactosylated collagen 
  A B C D E F Control 
 M-collagen (μl) 200 150 150 100 50 30 200 



















1.5 Imaging and characterization of nano-fibres in microcapsule 
For collagen nano-fibre characterization, microcapsules were imaged immediately 
after they were formed using an Olympus Fluoview 500 confocal microscope in  
backscattering mode using a 60x WLSM lens of NA 1.00 [236]. Optical sectioning of 
2µm was used to obtain a 3-D stack of the microcapsule. Image processing involved 
subjecting the images to a 10x10 gaussian filter, skeletonization and cropping to 
stacks of 200x200 pixel images, followed by macro calculation involving the 
following steps: calibration, intensity filter (threshold), area 5 filter and data 
extraction using Image-Pro Plus 4.5.1. Three physical parameters were retrieved from 
each optical slice and interpolated to 200 slices for each microcapsule (Matlab 6.0): 
area of dendrites (in pixels), dendritic length (total length of dendrites connected to a 
node in pixels), dendrite number (number of dendrites connected to a node) [236]. A 
dendrite was defined as a one pixel thick open branch, while a node as the point of 
origin of dendrites. The area of dendrites in each slice was divided over the total 
pixels in the slice to obtain the fractional area of dendrites for approximating the 
nano-fibre density profile in the microcapsule. To obtain indices of nano-fibre 
density, length and branching, the three physical parameters for each slice were 
averaged over the 10 centre slices (relatively homogeneous using 3% terpolymer) and 
normalized by setting values obtained from the slightly methylated collagen 
microcapsule as 1. 
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1.6 Image of dual staining of galactosylated collagen and methylated collagen in 
microcapsules[235] 
1.6.1 Methylated collagen conjugated by FITC 
5ml collagen solution (final concentration=2.7mg/ml) dissolved in PBS solution was 
added to the FITC PBS solution (10mg/ml). The mixture was reacted over night, after 
which the solution dialysed for 3 days till the Di-H2O is colourless.  
 
1.6.2 Galactosylated collagen conjugated by Rhodamine  
5ml collagen solution (final concentration 2.7mg/ml) dissolved in PBS solution was 
added to the Rhodamine PBS solution (10mg/ml). The mixture was reacted over 
night. Then the solution was dialysed for 3 days till the Di-H2O is colourless.  
 
1.6.3 Image the dual labelling collagen in microcapsules 
For characterizing the distribution of methylated and galactosylated collagen in 
microcapsules, microcapsules were imaged by an Olympus Fluoview 500 confocal 
microscope in  FITC and Rhodamine fluoresce mode and 60x WLSM lens of NA 1.00 



























M:G = 5: 1 83% M:G = 3: 1 83% M:G = 1: 1 83%

























M:G = 5: 1 38% M:G = 3: 1 38% M:G = 1: 1 38%
M:G = 1:3 38% M:G = 1:5 38%
 
Graph 6b 
Graph6 Permeability of different mixed ratios of galactosylated collagen and methylated 
collagen; Graph 6a the modification degree is 83%; Graph6 b the modification 







































M:G = 5: 1 16% M:G = 5: 1 38% M:G = 5: 1 83%
 
 
Graph7 Character of permeability of microcapsules prepared by the different modification 
degrees of galactosylated collagen, M: methylated collagen; G: galactosylated 















































Figurg.2  Profile of microcapsule and the surface morphology of microcapsules 










2.1 Permeability of different microcapsules 
From graph 6a and 6b, the amount of galactosylated collagen affects the permeability 
of microcapsules. With the increasing of galactosylated collagen, the permeability of 
microcapsules increased. Incubated in PBS for 60 minutes, the concentration of FITC-
dextran, which was released from microcapsules formed by galactosylated collagen 
and methylated collagen (mixed ratio=5:1), is 5.2mg/ml, while that is 7.3mg/ml, 
which was released from microcapsules formed by G-collagen and M-collagen 
(mixed ratio=1:5). From graph 7, there is no significant different permeability profile 
among microcapsules, which were made from different modification degree of G-
collagen. They are almost the same permeability characters profiles. At 60 minutes, 
the concentrations of FITC-dextran are all around 7mg/ml.  
The Figure 2 showed that the pore size of microcapsules, which were formed by the 
high concentration galactosylated collagen, is bigger than that of microcapsules, 
which were formed by the low concentration galactosylated collagen. The pore size of 
microcapsules, which were formed by the mixture of methylated collage and 
galactosylated collagen (mix ratio=1:5), is about 3 ± 1um, while the pore size of 
microcapsules, which were formed by the m-collagen and G-collagen (mix ratio=5:1), 
is about 10± 2um. Pore sizes of the microcapsules formed by the same ratio of M-
collagen and G-collagen were no significant different, even which were formed by 
different modification degree of the galactosylated collagen. When the mixed ratio of 
M-collagen and G-collagen is 5:1, pore sizes of microcapsules formed by 79%, 36%  
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X:Y:Z image 
M          M:G 5:1 
  
M:G 3:1                        M:G 1:1 
  













Figure 3 the nano-fiber in microcapsules formed by different mixed ratio of galactosylated 
collagen and methylated collagen. The X,Y,Z is the scanning direction; M: methylated 
collagen; G:galactosylated collagen; M:G is the mixed ratio of methylated collagen and  






and 18% modification degree galactosylated collagen were all about 10± 2 um. 
 
2.2 Imaging and Characterization of nano-fiber in microcapsules 
 
2.2.1 Image of nano-fiber in the microcapsules 
 
Form Figure 3, the density of nanofiber network decreased with the increasing ratio of 
galactosylated collagen in the mixture collagen (methylated collagen and 
galactosylated collagen.  
 
2.2.2 Quantization of nano-fiber density, dendritic length and number of dendrite 
 
Basing on the image analysis technical and confocal technical, the density, dendritic 
and length of nanofiber in the microcapsules have been investigated. The nanofiber 
structure is important for the hepatocytes and microcapsules support. In the graphic 8, 
9 and 10, the density of nanofiber in microcapsules formed by M-collagen alone 
cultured for 24 hours was defined as 1. 
 
From graph 8, 9, 10, the density, dendritic length and length of nanofiber in 100% m-
collagen are highest, otherwise, the density, dendritic length and length of nanofiber 
in microcapsules, which were formed only by G-collagen is the lowest, about 
0.92± 0.032. The length and dendritic length of nanofiber in microcapsules formed by 
glacatosylated collagen are also the lowest. On the other hand, the length of nanofiber 
in microcapsules, which were formed by galactosylated collagen is only 44%, while 
that in microcapsules, which were formed by methylated collagen only, was defined 
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as 100%. While the area and dentric of nanofibers in G-collagen formed 
microcapsules are about 92% and 58%, while those of nanofibers in microcapsules 
formed by methylated collagen only were all defined as 100%, respectively.  
 
2.3 Imaging dual staining of galactosylated collagen and methylated collagen in 
microcapsules 
 
From the figure 3, the green channel showed that the methylated collagen located on 
the nanofiber only. But the red channel showed that the galactosylated collagen 
located not only on nano fiber, but also in the solution. Form the overlap image. The 
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Graph8 Number of dendric in microcapsules prepared by different mixed ratios of 
galactosylated collagen and methylated collagen. The percentage is the 






































































Graph9 Length of dendric in microcapsules prepared by different mixed ratios of 
galactosylated collagen and methylated collagen. The percentage is the 


















































































Graph10 Density of nanofiber in microcapsules prepared by different mixed ratios of 
galactosylated collagen and methylated collagen. The percentage is the 

































Figure4 Dual labeling of methylated collagen (green) and galactosylated collagen (red) 
mixed in 1:1 ratio with FITC and rhodamine 6G respectively. (A) FITC-labelled methylated 
collagen. (B) Rhodamine-labelled galactosylated collagen; inset shows negative control 
made with unlabelled galactosylated collagen and FITC-labelled methylated collagen in 1:1 
ratio imaged under same settings. (C) Overlay of green and red channels shows that 
methylated collagen and galactosylated collagen co-localize at the nano-fibres (yellow), but 











From the graph 6, the permeability character of different microcapsules formed by 
different modification degrees is not significant different. But from the graph 5a and 
5b, the higher the concentration of G-collagen, the higher permeability the 
microcapsules is. The permeability of microcapsules is mainly affected by the density 
of network on surface of microcapsules and the net work inside microcapsules. The 
reason may be that the network in the surface of microcapsules mainly formed by the 
m-collagen and polymer. On the other hand, the nanofiber network inside 
microcapsules also mainly formed by the M-collagen. The previous work  also shows 
that the fibers in microcapsules are mainly formed by M-collagen, while the G-
collagen distributes both in the fiber and solution of microcapsules[235]. The image 
of surface of microcapsules by SEM also showed that the pore size of different 
microcapsules formed by same mixed ratio of M-collagen and G-collagen, but 
different modification degree are almost same, about 10um± 2um(when the mixed 
ratio of G-collagen and M-collagen is about 5:1). But when the modification degree of 
G-collagen is same, with the increasing of G-collagen, the pore sizes also increase. 
When the mixed ratio of G-collagen increased from 17% to 83% in the mixture of M-
collagen and G-collagen, the pore sizes of the surface of microcapsules incresed form 
2um to 10um. 
 
The fiber density, length and dendritic number of nano-fiber formed by modified 
collagen increase with the increasing ratio of G-collagen in the mixture collagen. This 
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result is also consistent with the result of permeability experiment. This implies that 
the fiber in microcapsules will mainly affected by the M-collagen. The nano-fiber of 
modified collagen was formed in microcapsules mainly by the force of hydrophobic 
and ion charge. However, the collagen modified by the galactose group was 
introduced many hydrophilic groups, consequently the hydrophobic force decreases. 
On the other hand, the large size of galactose group and long spacer make the chain of 
collagen difficult to aggregate to form the fibers in solution. On the contrary, the 
methylated collagen, which was conjugated by a small and hydrophobic group, makes 
the collagen chain easy to aggregate to fibers.  
 
The density of fiber in microcapsules formed by 83% G-collagen is about the 92% of 
that in microcapsules formed by M-collagen, but the fiber length and fiber dendritic 
length in microcapsules formed by 83% G-collagen is only about the 44% and 58% of 
those in microcapsules formed by M-collagen. And our previous work showed that 
the fibers in microcapsules were mainly formed by M-collagen and the G-collagen 
distributed both in fiber and solution. The result showed the average area of fiber in 
microcapsules formed by 83% G-collagen is larger than those in microcapsules 
formed by M-collagen. That imply that the M-collagen is easier to form nano-fibers 
and G-collagen would like to attach to the nano-fibers.  
 
The nanofiber is formed by methylated collagen and galactosylated collagen. On the 
other hand, mthylated collagen only locates in the nanofiber. So the skeleton of 
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microcapsules was made from the methylated and galactosylated collagen. From the 
different density of nanofiber density, the more galactosylated collagen in 
microcapsules, the less density nanofibers were. Therefore, methylated collagen and 
part galactosylated collagen contribute the mechanical support of microcapsules and 
hepatocytes in microcapsules. The galactose group and oligo-peptide resides on 
galactosylated collagen, which were in solution attached to hepatocytes in 
microcapsules. So the possible structure in microcapsules is that hepatocytes were 
conjugated galactosylated collagen, which were attached to nanofiber formed by 
galactosylated collagen and methylated collagen. 
 
4. Conclusion 
Characters of microcapsules formed by methylated collagen and galactosylated 
collagen have been investigated in this section. The ratios of galactosylated collagen 
in the modified collagen mixture affect the microcapsule surface characters and 
nanofiber formed by methylated collagen and galactosylated collagen in microcapsule. 
Therefore, the character of permeability is also influenced by the ratio of 
galactosylated collagen. The galactosylated collagen distributes in both nanofiber and 








Chapter4 Morphology and enhanced cell functions of hepatocytes in 
the microcapsules formed by C-galactosylated collagen 
 
In this study, Basing on the interaction between ASGPR and the galactose group, the 
galactose group was conjugated to the carboxyl group of collagen to enhance the 
attachment of hepatocytes in microcapsules. The galactosylated collagen mixed with 
methylated collagen encapsulated hepatocytes with poly(HEMA-MMA-MAA). The 
morphology of Hepatocytes encapsulated in the collagen microcapsules has been 
imaged by the light microscopy. The pictures showed the hepatocytes aggregated in 
microcapsules. Cell functions of hepatocytes in microcapsules have been tested.  
 
1. Materials and Methods 
1.1 Materials 
Urea assay kit (Sigma), 7-ethoxycoumarin (sigma), ß-glucuronidase(sigma), 
sulfatase(sigma), 7-hydroxycoumarin(sigma), rat-albumin ELISA kit(Pierce) 
 
1.2 Isolation of rat hepatocytes 
Hepatocytes were harvested from male Wistar rats weighing from 250 to 300 g by a 
two-step in situ collagenase perfusion as described previously,[10] with some 
modifications. The rat was given 100 U/kg of heparin 30 min before anesthesia; 
pentobarbital was administered at a dose of 30 mg/kg, intraperitoneally at the start of 
the operation. After laparotomy, a portal cannula was placed and fixed in a position 
along the portal vein. A cut was rapidly made in the lower vena cava. In the initial 
 96
first 2–3 min, pre-perfusion (with Ca21-free perfusion buffer) was reformed while the 
liver remained in situ. The perfusion flow was started at a rate of 50 mL per minute. 
While preperfusion was carried out, the liver was transferred to a petri dish and placed 
in a position similar to its in situ site. After 10 min of preperfusion with Ca21-free 
medium, the liver was then perfused with recirculating 0.05% collagenase buffer for 
another 10 min. This was terminated when the vena cava ruptured. The entire 
perfusion procedure was performed under oxygenation that greatly improved the cell 
viability. The cells were liberated from the connective vascular tissue and 
resuspended in fresh growth medium. This was followed by incubation of the cell 
suspension in a 37°C CO2 incubator for 30 min. The cell suspension was then filtered 
through a nylon mesh with a 60-mm pore size to further remove the connective tissue 
debris. The filtrate was then centrifuged at 50 g for 1 min to obtain the cell pellet. The 
cells were collected and washed twice with growth medium. The viability of the 
hepatocytes was determined to be 90–95% in all cases using the conventional Trypan 
Blue exclusion Test. [236] 
 
1.3 Morphology of hepatocyte in the microcapsules 
1.2.1 Imaging of hepatocytes in microcapsules by light microscopy 
The encapsulated hepatocytes were cultured in hepatozyme for 5 days. The change of 
morphology of hepatocytes was detected by the light microscopy every two days. 
 
1.4 Cell functions of hepatocytes in microcapsules 
1.4.1 Urea assay 
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To investigate the urea production of the hepatocytes, 200µl of microcapsules 
(containing a total of 1x106 cells) were incubated in medium with 1 mM NH4Cl for 
90min and the medium analyzed by the Urea Nitrogen Kit (Sigma Diagnostics). 
 
1.4.2 Cytochrome P450 assay 
7-ethoxycoumarin O-deethylase (ECOD) activity was accessed by measuring the 
concentration of metabolic product, 7-hydroxycoumarin by High Performance Liquid 
Chromatography (HPLC). Briefly, the reaction was initiated by incubating 1x106 
encapsulated hepatocytes (200µl microcapsules) with 0.26 mM 7-ethoxycoumarin for 
3h at 37°C, after which the medium was aspirated and the 7-hydroxycoumarin 
conjugates hydrolyzed with enzymes ß-glucuronidase and sulfatase at 37°C. The 
medium was then mixed with chloroform, saturated sodium borate buffer, and internal 
standard (4-methylcoumarin) for 10min. The chloroform layer was subsequently dried 
at 60°C and dissolved in the dilution buffer (water: methanol = 1:1). The samples 
were tested by HPLC with calibration curve.  
 
1.4.3 The rat albumin secretion of microencapsulated hepatocytes 
The production of albumin by the encapsulated hepatocytes was determined by 
performing a enzyme-linked immunosorbent assay (ELISA) analysis.[238] First, 100-
uL rabbit anti-rat albumin antibody diluted by coating buffer at the ratio 1:100 was 
coated in the 96 well-plate and incubated at 4 degree over night. The unabsorbed 
antibody were discarded and washed with tris-tween 20 buffer (wash buffer, pH=8.0) 
3 times for 15 min. The coated plate was blocked with 3% BSA-tris 8.0 buffer 
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overnight at 4 degree. The block buffer was discarded and the plate was washed by 
wash media 3 times for 15 minutes, after which 100ul samples (medium collected at 
various time points) diluted by 200 times as well as a series of known concentrations 
of rat albumin were added to the plate (NUNC) and incubated at 4 degree overnight. 
The unreacted sample was discarded and the late was washed by wash buffer 5 times 
for 25 min. Next, 100 uL of the horseradish peroxidase (HRP)-conjugated anti-rat 
albumin antibody (ICN) at a dilution of 1:5000 was added into each well and the plate 
incubated at room temperature for an additional 1 h. the reaction was stopped by 2M 
H2SO4. The amount of albumin was quantified by the conversion by HRP of TMB 
catalysis by H2O2, a colormogeny (Sigma) to its soluble end-product, which has an 
absorption maximum at 450 nm, with reference to the standard albumin curve derived 
from known concentrations of rat albumin. 
 
2 Results 
In this study, effects of different modification degrees, different mixed ratios and cell 
density to cell functions of hepatocytes in microcapsules have been studied. 
2.1 Morphology of hepatocytes in microcapsules 
Figure 5 and 6 showed the aggregation of hepatocytes in microcapsules. With the 
increasing of culture time (from day 1 to day 5), degrees of aggregation increased. In 
the figure 5, the high modification degree G-collagen was introduced in the 
microcapsules and the mixed ratio of M-collagen and G-collagen were from 100% to 
25%. With the increasing of M-collagen, the aggregation degree decreased. In the 
figure 6, the same mixed ratio of M-collagen and G-collagen was used to form 
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microcapsules, while the modification degrees of G-collagen were from 18% to 79%. 
Hepatocytes in mixture of G-collagen and M-collagen aggregate more easily than 
hepatocytes in only m-collagen. There are no significant differences among 






























Figure5 the morphology of hepatocytes in microcapsules in different days. The different 
mixed ratios of galactosylated collagen and methylated collagen are from 1:3 to 3:1. M: 
methylated collagen; G: galactosylated collagen 
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Figure6  the morphology of hepatocytes in microcapsules in different days. The same mixed 
ratio of galactosylated collagen and methylated collagen and different modification degree. 
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Graph11 Urea functions of hepatocytes in microcapsules formed by different modification G-


























































2.2 Optimized Cell functions of hepatocytes in microcapsules prepared by 
different modification degree galactocylated collagen 
2.2.1 Urea production  
Graph 11 showed that ammonia functions of hepatocytes were the highest in the first 
day and then dropped from the second day. With the increasing of galactosylated 
modification degree of collagen, the ammonia metabolism function also increased. 
When the modification degree of galactose group is 0 %( control), the urea 
concentration was about 31mg/l; as the modification degree of galactose group was 83 
%( 1A), the urea concentration was 95mg/l. When the mixed ratio of G-collagen and 
M-collagen was 1:1, the concentration of urea in microcapsules formed by higher 
modification degree of G-collagen was also higher than those in microcapsules 
formed by lower modification degree of G-collagen. The urea concentration of sample 
1B was 70mg/l at the first day, while that of sample 3B was 55mg/l. 
 
2.2.2 7-ethoxycoumarin O-deethylase (ECOD) activity 
Graph 12 showed that hepatocytes in microcapsules formed by higher modification 
degree G-collagen showed higher cyto P450 enzyme activity. In microcapsules 
formed by the same mixed ratio of methylated collagen and galactosylated collagen 
(1:3), the concentration of 7-Hydorcycomourin was 11.8mg/l in microcapsules formed 
by 83% modification degree galactosylated collagen, while the concentration of 7-
HCOD was only 4.8mg/l in microcapsules, which was prepared by 18% modification 
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degree G-collagen. At the seventh day, the cell function of hepatocytes in 
microcapsules formed by highest modification degree galactosylated collagen was 
also much higher than the function of hepatocytes in microcapsules formed by lower 
modification degree galactosylated collagen. The concentration of 7-HCOD in sample 
1A was 3.8mg/l at day7 and that of 7-HCOD in sample 1B was 1.8 mg/l, while the 
concentration of 7-HCOD in sample 3A and 3B was only about 1.5 mg/l. 
 
2.2.3 rat-albumin production 
Graph 13 showed that the amount of rat albumin is the highest at the third day. The 
data in graph 13 also showed that the amount of secreted albumin increased with the 
increasing of modification degree of G-collagen. The concentration of albumin in 
sample 1A was 28ug/ml at the second day, while that in sample 3a was about 22ug/ml 
at the same day. When the mixed ratio of G-collagen and M-collagen was about 1:1, 
the concentration of albumin in sample 1B was 21ug/ml, while that in sample 3B was 
21ug/ml. at the seventh day, the concentration of albumin in sample 1A was about 14 
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Graph12 P450 enzyme activities of hepatocytes in microcapsules formed by different 


















































2.3 Optimized cell functions of hepatocytes in different mixed ratio of 
galactosylated collagen and methylated collagen 
 
2.3.1 Urea production 
The data in graph 14 showed that when the mixed ratio of galactosylated collagen and 
methylated collagen was 3:1, the urea concentration was the highest. At the first day, 
when the mixed ratio of galactosylated collagen and methylated collagen was 3:1, the 
urea concentration was 87mg/l. When the galactosylated collagen was equal to 
methylated collagen in the mixed collagen, the urea concentration in the 
microcapsules increased significantly. When the mixed ratio of galactosylated 
collagen and methylated collagen was 1:3, the urea concentration was 47mg/l, but 
when the mixed ratio reached 1:1, the urea concentration was about 73mg/l. 
 
2.3.2 7-ethoxycoumarin (7-ECOD) O-deethylase activity 
From graph 15, the activity of p450 enzymes was the highest in microcapsules formed 
by the mixed galactosylated collagen and methylated collagen whose mixed ratio was 
3:1. at the first day, the concentration of 7-HCOD was 13mg/l in the sample E, while 
that was 8.2mg/l in sample A. the concentration of 7-HCOD in sample control was 
8.2mg/l too. At the seventh day, the concentration of 7-ECOD in sample E was also 




2.2.3 Rat-albumin production 
From the graph 16, the concentration of rat albumin in microcapsules formed by 
galactosylated collagen  and methylated collagen was higher than that in 
microcapsules formed by only methylated collagen. When microcapsules were 
formed by the mixture collagen whose mixed ratio was 1:3(methylated collagen: 
galactosylated collagen), the concentration of albumin was the highest. The 
concentration of albumin in sample E was 26 mg/l at the second day, while that in 
sample A was 17ug/ml at the same day. At the seventh day, the concentration of 








































Graph14   Urea function of hepatocytes in microcapsules formed by different mixed ration 
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Graph15   P450 enzyme activity of hepatocytes in microcapsules formed by different 





























































Graph16 Amount of rat albumin of hepatocytes in microcapsules formed by different mixed 












2.3 Optimized cell functions of hepatocytes at different seeding cell density 
2.3.1 Urea production 
From figure 17, the urea production is highest when the seeding density was 
5.00X106/ml. Urea production was 107 mg/ml at the first day when 5X106 
hepatocytes/ml were seeded. But urea production was only less than 63mg/ml and 71 
mg/ml at day1 when seeding densities of hepatocytes was 1.00X107 and 2.5X106 
respectively.  
2.3.2 7-ethoxycoumarin (7-ECOD) O-deethylase activity 
Figure 18 showed that activities of P450 enzyme were highest when the seeding cell 
density was 5.00X106cells/ml. When the cell seeding density was 5X106cells/ml the 
production of 7-HCOD was above 20 mg/ml at first day, while those were 18mg/ml 
and 15mg/l when the seeding densities were 1X107cells/ml and 2.5X106cells/ml. 
2.3.3 rat-albumin production 
From figure 19, the trend of cell functions was the same as the above two functions 
(Urea production and activities of 7-ethoxycoumarin O-deethylase). The production 
of rat albumin of hepatocytes is about 25mg/ml at the third day while the seeding 
density was 5X106cells/ml. The concentration of rat albumin were about 21mg/ml and 









































1X10^7/ml (add in 0.2E6 cells) 5X10^6/ml (Add in 0.1E6 cells) 2.5X10^6/ml (Add in 0.1E6 cells)
 
 



















































































s) 1X10^7/ml (add in 0.2E6 cells)
5.X10^6/ml (Add in 0.1E6 cells)





















































3 Discussions  
Hepatocytes in microcapsules aggregated during cultured in hepatozyme. Hepatocytes 
in microcapsules formed by the methylated collagen and galactosylated collagen were 
easier to aggregate than those in microcapsules formed by the methylated collagen. 
On the other hand, Hepatocytes in microcapsules formed by the higher mixed ratio of 
galactosylated collagen are easier to aggregate than those in microcapsules formed by 
lower mixed ratio of galactosylated collagen, But there are no significant different 
among hepatocytes in microcapsules formed by the different modification degree 
galactosylated collagens. The result implies that the density of nanofibers influences 
the aggregation of hepatocytes in microcapsules. The aggregation of hepatocytes in 
microcapsules is not related to the galactose group. Different ratios of methylated 
collagen in the mixture of modified collagen affect the density of nanofibers in 
microcapsules which have been proved by previous work [235]. However, with the 
increasing of galactosylation degree of collagen, the density of nanofiber is not 
significant different. Therefore, hepatocytes in low density fibers microcapsules can 
move easily and attach each other easily.  
From the data of cell functions of hepatocytes in microcapsules, the higher 
modification degree of G-collagen in microcapsules can enhance the cell functions of 
hepatocytes, but in the microcapsules formed by different mixed ratio of G-collagen 
and M-collagen, cell functions did not increase with the increasing of amount of 
galactose group. Results imply that the galactose group in microcapsules really can 
enhance the function of hepatocytes in microcapsules. However, the results also imply 
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as our previous research [235] that cell functions of hepatocytes were affected by both 
the galactose group and the nanofiber network formed by modified collagen. Briefly, 
we hypothesized that both the physical and chemical properties of the collagen nano-
fibers would be important for hepatocyte support. We compared the differentiated 
functions of hepatocytes cultured in mixtures of slightly methylated and 
galactosylated collagen with varied proportions of physical support and galactose 
interactions. The urea production and ECOD activity of hepatocytes were enhanced as 
the percentage of galactosylated collagen in the collagen mixture increased until a 
peak at 75% galactosylated collagen, after which any further increase in 
galactosylated collagen led to a deterioration of its functions instead. Since collagen 
nano-fibers with greater proportions of galactosylated collagen possess lower fiber 
connectivity, the results suggest that the stimulation of hepatocyte functions by the 
galactose-ASGPR interactions is limited by the physical support. Conversely, 
collagen mixtures with greater fiber connectivity but lower amounts of galactose 
perform poorer because of the fewer galactose-ASGPR interactions. Our results 
indicate that optimization of the physical and chemical parameters of the ECM are 
important for maintaining hepatocyte functions in vitro. 
 
The optimized cell density of hepatocytes for seeding into the galactosylated 
microcapsules is 5X106/ml. The possible reason is that the cell-cell interaction is 
important for hepatocytes, which are anchorage-dependent cells. Otherwise the mass 
transfer is also another key point for hepatocyte survival. When 1.5X106/ml 
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hepatocytes are entrapped in microcapsules, cell-cell interaction of hepatocytes is less. 
While 10X106/ml hepatocytes are trapped in microcapsules, the high density of 
hepatocytes limits the mass transfer. 
   
The different time trend between secretions of rat albumin and ammonia transferases 
implies that the network in microcapsules affects the mass transfer characters. Briefly, 
microcapsules can affect the big molecule proteins transfer, such as rat albumin. 
However, the small molecule, NH4+, will not be limited by the fiber network of 
microcapsules.    
 
From results of hepatocyte functions prepared by different conditions, the optimized 
conditions for hepatocytes in galactosylated collagen ECM is the highest modification 
degree of galactosylated collagen(83%), the suitable mixed ratio of galactosylated 
collagen and methylated collagen(galactosylated collagen: methylated collagen=3:1), 
and suitable cell seeding density(5.00X106) 
 
4. Conclusion 
Galactose group, which interacts with the hepatocyte by the cell surface 
receptor(ASGPR), and nanofiber network, which provides mechanical support to 
hepatocytes in microcapsules, are both important to maintain cell functions and 
survival of hepatocytes. The galactose group can enhance cell functions of 
hepatocytes through the signal pathway. On the other hand, the mechanical support 
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can enhance cell functions of hepatocytes through mechanical support.  
The cell-cell interaction is a critical factor of in vitro cell culture. So the optimized 
seeding cell density can enhance cell functions in microcapsules. 
From results of hepatocyte functions prepared by different conditions, the optimized 
conditions for hepatocytes in galactosylated collagen ECM is the highest modification 
degree of galactosylated collagen(83%), the suitable mixed ratio of galactosylated 
collagen and methylated collagen(galactosylated collagen: methylated collagen=3:1), 
















Chapter 5:  In situ gelation of galactosylated collagen to develop a 3D 
culture for enhanced hepatocyte functions 
 
In vivo, hepatocytes are supported in specific architectures imposed by extra-cellular 
matrices (ECM) comprising a 3-D environment with other collagen and many types of 
glyco-proteins. These ECMs play crucial roles for cell-viability and also serve an 
important function as scaffolds. Collagen is wildly used biomaterials for cell culture 
[1]. There are also other studies to evaluate the relationship between the polymer 
molecular weight and the mechanical strength. [238] The fibrin network has also been 
used to enhance the mechanical strength of microcapsules. [136] 
 
Our previous work showed that cell functions of hepatocytes in 3-D environment, 
such as microcapsules, are much better than those in 2-D culture [139]. However, the 
modified collagen microcapsule is not strong enough for many applications in liver 
tissue engineering. So we created in situ gelation scaffold as device for liver tissue 
engineering. 
 
The principle of in situ gelation of galactosylated collagen is that the boronic acid 




We have prepared a porous hydrogel and in situ forming galactosylated system for 3-
D cell culture of hepatocytes. In this study, the PHEMA was initiated by AIBN and 
crosslinked by PEG-diacrylated. The different particle sizes of  NaCl were mixed with 
the reaction solution to form pores in the PHEMA scaffold. The galactosylated 
collagen was used as ECM for 3-D hepatocytes culture. Porous PHEMA was used to 
contain hepatocytes which were entrapped by in situ gelation galactosylated collagen. 
The permeability character of PHEMA hydrogel has been studied. Swelling ratios of 
PHEMA have also been evaluated. Hepatocytes were seeded in different crosslinking 
degree in situ gelation galactosylated collagen. Cell functions (ammonia function, 
P450 function and rat albumin) of hepatocytes have been evaluated.  
1. Materials and methods 
1.1 Materials 
Galactosylated collagen; APBS; porous PHEMA scaffolds; glutaraldehyde (GA); 
AIBN  
1.2 Formation of galactosylated collagen fiber by 1,4-Aminophenylboronic acid-
succinic acid(APBS) on coverslip  
The galactosylated collagen (3mg/ml) mixed with APBS (0.5mg/ml) was coated on 
coverslips. Coverslips were incubated at 37 ºC for different time, (15mins, 30mins, 
60mins, and 120mins), after which Coverslips were immersed in DI-water and 
washed three times. Then coverslips were fixed by glutaraldehyde (5%) at room 
temperature for 3 hours and freezing-dried for three days. The network of collagen on 






















Scheme6 Principle of in situ gelling galactosylated collagen gel  








1.3 Cell morphology of hepatocytes entrapped by in situ formatting scaffold 
in PHEMA scaffold 
Hepatocytes (10X106/ml, 500ul), Galactosylated collagen (3mg/ml, 500ul) and 
different amount of APBS (from 10 ug to 0.625ug) was put on scaffolds. The culture 
plates were incubated at 37 ºC for 24 hours. Scaffolds were removed from culture 
plates and fixed by glutaraldehyde (5%) for 3 hours, after which scaffolds were 
washed by DI-water for 3 times and freezing-dried under 33X10-3Pa. The morphology 
of hepatocytes in scaffold was detected by SEM.   
 
1.4 Adhesion of hepatocytes in different collagen and crosslinker concentration 
hepatocytes (10X106/ml, 200ul) mixed with galactosylated collagen (final 
concentration=1.5mg/ml, 100ul) and different amount of APBS solution (100ug/ml, 
from 10 to 100ul) was seeded in dried porous PHEMA scaffold. The media was 
changed after one day. The hepatocytes in media were counted to evaluate the seeding 
efficiency of hepatocytes in this system.   
 
1.5 cell function assays  





















Table 5 in situ gelling galactosylated collagen to entrap hepatocytes in PHEMA in vitro 
 
 APBS(ug) Galactosylated collagen(ul) Native collagen(ul) Media(ul)
S1 0.625 500 0 500 
S2 1.25 500 0 500 
S3 2.5 500 0 500 
S4 5 500 0 500 
S5 10 500 0 500 
Control 1 0 0 500 500 
Control 2 0 500 0 500 
 






















2.1 The toxicity of APBS crosslinking reagent. 
 
 
The Galactosylated collagen mixed with hepatocytes was crosslinked by the APBS. 
The APBS is a novel chemical for hepatocyte culture. So the toxicity of APBS should 
be studied. From graph 20, the viability of hepatocytes is almost the same, in APBS 
solution whose concentration is from 0.01mg/ml to 1 mg/ml. The viability of 
hepatocytes is 77% in the 1mg/ml APBS-hepatozyme solution, while the viability of 
those in the hepatozyme is 81%. P value is much more than 5% by t-test. That means 
the viabilities of different sample are not significantly different. 
 
2.2 Efficiency of hepatocyte adhesion in PHMEA scaffold 
 
From the graph 21, Seeding efficiency of hepatocytes entrapped by the in situ gelation 
galactosylated collagen system increased with the increasing of amount of APBS. 
There are only about 51% hepatocytes entrapped by the scaffold (PHEMA). 73% 
hepatocytes were entrapped in galactosylated collagen solution without APBS. While 
the 2.5ug APBS was mixed with G-collagen, 85% hepatocytes were entrapped. 
 
2.3 Network formed by the mixture of  galactosylated collagen and APBS 
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The galactosylated collagen reacted with APBS to form in situ forming scaffold. 
Figure 7 showed that the density of network increased with the increasing of 
incubation time. After being incubated for 150 minutes, the galactosylated collagen 
was formed a fiber network. There is no significant different density of fiber network 
between two different incubation times, 1 day and 150 minutes.  
 
2.4 Morphology of hepatocytes entrapped by the in situ gelation collagen in 
porous PHEMA scaffold 
 
From Figure 8, when the more APBS was added, the fiber density of galactosylated 
collagen was higher. The network density of galactosylated collagen in which there 
was no APBS, was very low. More hepatocytes were entrapped in higher fiber density 
network of the in situ gelation G-collagen. However, more cell aggregate in lower 

















































 Graph20 Toxicity of APBS in the hepatocytes cultured on collagen gel; 
















































Graph21 Attachment of hepatocytes captured in galactosylated collagen in porous PHEMA 
S1-S5 were showed in table5; galactosylated collagen is that hepatocytes were entrapped 
by galactosylated collagen without APBS; PHEMA is that hepatocytes were entrapped by 
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Figure7 In situ formatting of galactosylated collagen and APBS  
The APBS was mixed with galactosylated collagen and fixed by glutaraldehyde and 
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2.5 Cell functions of hepatocytes entrapped by in situ gelling G-collagen in 
porous scaffold PHEMA (NaCl particle size=200) 
 
 
From Graph 22, 23, 24, three cell functions of hepatocytes, which were entrapped by 
in situ gelling collagen in porous PHEMA, have the same trend. When the 0.625ug 
APBS was added in the galactosylated collagen, cell functions were the highest. The 
concentration of urea is 120 µg/ml at the first day; the concentration of 7-HCOD is 
17µg/ml at the first day; the concentration of rat albumin is 25 µg/ml at the third day. 
With the increasing of APBS, cell functions of hepatocytes decreased. When 10ug 
APBS were added in galactosylated collagen, the concentration of urea is about 80 
µg/ml at the first day; the concentration of 7-HCOD is 10 µg/ml; the concentration of 
rat albumin is about 14 ug/ml at the third day. Cell functions of hepatocytes entrapped 
by native collagen gel in the porous PHEMA scaffold is lower than those entrapped 
by in situ gelling in the porous PHEMA scaffold. The concentration of urea is about 
60 µg/ml at the first day; the concentration of 7-HCOD is about 8 µg/ml at the same 
day; the concentration of rat albumin is 13 µg/ml at the third day. However, cell 
functions of hepatocytes captured by only galactosylated collagen were much lower 
than those entrapped by in situ gelation galactosylated collagen gel. The concentration 
of urea is about 56 µg/ml at the first day; the concentration of 7-HCOD is  7µg/ml at 


















































Graph22 Urea production of hepatocytes captured in situ gelling galactosylated collagen in 
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Graph23 Concentration of 7-HCOD in the scaffold. S1-S5, control1 and control 2 were 



















































Graph24 Rat- albumin productions of hepatocytes captured by in situ gelling collagen in 






3. Discussion  
3.1 Entrapping efficiency of hepatocytes by the in situ gelation galactosylated 
collagen in PHMEA scaffold. 
 
The hepatocytes are anchorage dependent cells, the attachment of hepatocytes in the 
scaffold is very important for the cell survival and cell functions of hepatocytes in the 
scaffold in vitro. In graph 21, the seeding efficiency of hepatocytes increased with the 
increasing of APBS. It implies that the seeding efficiency of hepatocytes depends on 
the crosslinking degree of galactosylated collagen. From the picture of the 
morphology of hepatocytes entrapped by the in situ galactosylated collagen in the 
porous HPEMA scaffold. The more APBS was added, the crosslink degree of 
galactosylated collagen was higher. In the higher density galactosylated collagen, 
more hepatocytes can be entrapped in the scaffold. The native collagen gel can also 
entrap hepatocytes. Therefore, there are no significantly different between the seeding 
efficiency of hepatocytes in native collagen and in the in situ gelation galactosylated 
collagen gel. However, galactosylated collagen cannot form gel by itself, therefore, 
only 50% hepatocyte were entrapped by galactosylated collagen in the porous HEMA.  
 
3.2 Relationship between scaffold structure and cell functions of hepatocytes 
The more ABPS was added, the lower cell functions of hepatocytes are. From the 
result of the toxicity of APBS, APBS is non-cytotoxicity for hepatocytes under 
1mg/ml. therefore; the APBS is not the reason of the decreasing cell functions with 
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the increasing of concentrations of APBS. This implies that unconjugated galactose 
groups and the mass transfer characters of the in situ gelling collagen enhance cell 
functions of hepatocytes in scaffolds. ABPS molecule will conjugate to galactose 
groups to form covalent bond. The more ABPS was mixed with galactosylated 
collagen, the less unconjugated galactose groups were. Many researches have showed 
that the galactose group can enhance the cell functions of hepatocytes in scaffolds [92, 
93, 94, and 95]. Therefore, more galactose group will benefit to the cell functions of 
hepatocytes entrapped by the in situ gelling collagen in porous PHEMA scaffolds. The 
other possible reason is mass transfer character of in situ gelling galactosylated 
collagen in scaffolds. From the figure 7, the higher density network of galactosylated 
collagen was formed while more APBS was mixed with galactosylated collagen. 
Therefore, the efficiency of mass transfer is lower, when more APBS was added. 
The hepatocyte is an anchorage dependent cell. The mechanical support is also 
important for maintaining cell functions of hepatocytes in vitro, which also be proved 
by results of galactosylated collagen microcapsules. Cell functions of hepatocytes 
seeded with galactosylated collagen alone are much lower than those seeded with 
galactosylated collagen and APBS. The possible reason is that the G-collagen alone 
cannot provide enough mechanical support to hepatocytes because the galactosylated 
collagen cannot form gel in porous PHEMA alone. In the solution of the 
galactosylated collagen alone, hepatocytes cannot attach to the galactosylated 
collagen scaffold. It implies that the mechanical support is important for maintaining 




The in situ gelation galactosylated collagen gel is a useful gelling system for culturing 
hepatocytes in vitro. The galactosylated group on modified collagen can enhance cell 
functions of hepatocytes in vitro, while the in situ gelling system can provide enough 
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